DiCE Clinical Trials Database

Patients undergoing treatment often ask about the possibility of enrolling in a clinical trial. A clinical trial is a scientific study. It tests new molecules in the hope that they are safe and more effective than current treatments.

This database is based on clinicaltrials.gov – a global clinical trials database of all diseases and all molecules in development worldwide. It is a shortened version of this, focusing on current clinical trials related to digestive cancers in Europe. The information is updated daily.

Important to remember: please always discuss with your treating physicians first your considerations of partaking in a clinical trial. They are the best judges of its benefits to your particular case.

NCT IDNameStudy typePhaseStatusCountryDisease typeMore infos
NCT00002692Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the LiverInterventionalPhase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT00002692Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the LiverInterventionalPhase 3Unknown statusUnited KingdomMetastatic CancerInfos
NCT00002793Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal CancerInterventionalPhase 3Unknown statusGermanyColorectal CancerInfos
NCT00002793Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal CancerInterventionalPhase 3Unknown statusGermanyMetastatic CancerInfos
NCT00002884Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the EsophagusInterventionalPhase 3Unknown statusFranceEsophageal CancerInfos
NCT00002893Palliative Chemotherapy in Treating Patients With Advanced Colorectal CancerInterventionalPhase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT00002896Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal CancerInterventionalPhase 3Unknown statusItalyColorectal CancerInfos
NCT00003063Biological Therapy With Combination Chemotherapy in Patients With Colorectal CancerInterventionalPhase 3Unknown statusGreeceColorectal CancerInfos
NCT00003063Biological Therapy With Combination Chemotherapy in Patients With Colorectal CancerInterventionalPhase 3Unknown statusItalyColorectal CancerInfos
NCT00003260Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal CancerInterventionalPhase 3Unknown statusFranceColorectal CancerInfos
NCT00003617Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the StomachInterventionalPhase 3Unknown statusPolandGastric CancerInfos
NCT00003617Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the StomachInterventionalPhase 3Unknown statusSwitzerlandGastric CancerInfos
NCT00003617Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the StomachInterventionalPhase 3Unknown statusUnited KingdomGastric CancerInfos
NCT00004115Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and ChemotherapyInterventionalPhase 3Unknown statusUnited KingdomOvarian CancerInfos
NCT00004115Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and ChemotherapyInterventionalPhase 3Unknown statusUnited KingdomPrimary Peritoneal Cavity CancerInfos
NCT00004236Liposomal Doxorubicin in Treating Patients With Advanced Stomach CancerInterventionalPhase 2Unknown statusUnited KingdomEsophageal CancerInfos
NCT00004236Liposomal Doxorubicin in Treating Patients With Advanced Stomach CancerInterventionalPhase 2Unknown statusUnited KingdomGastric CancerInfos
NCT00006112Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal CancerInterventionalPhase 2Unknown statusFranceCarcinoma of the AppendixInfos
NCT00006112Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal CancerInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00006112Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal CancerInterventionalPhase 2Unknown statusFrancePrimary Peritoneal Cavity CancerInfos
NCT00006115Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00006117Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusBelgiumPancreatic CancerInfos
NCT00006117Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusFrancePancreatic CancerInfos
NCT00006468Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal CancerInterventionalPhase 3Unknown statusFranceColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusAustriaColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusAustriaMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusBelgiumColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusBelgiumMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusFranceColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusFranceMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusGermanyColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusGermanyMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusItalyColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusItalyMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusNetherlandsColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusNetherlandsMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusNorwayColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusNorwayMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusPortugalColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusPortugalMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusSwedenColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusSwedenMetastatic CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT00006479Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal CancerInterventionalPhase 3Unknown statusUnited KingdomMetastatic CancerInfos
NCT00007826Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal CancerInterventionalPhase 1/Phase 2Unknown statusUnited KingdomColorectal CancerInfos
NCT00008047Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the EsophagusInterventionalPhase 1/Phase 2Unknown statusFranceEsophageal CancerInfos
NCT00010062Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic CancerInterventionalPhase 2Unknown statusFrancePancreatic CancerInfos
NCT00010062Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic CancerInterventionalPhase 2Unknown statusLuxembourgPancreatic CancerInfos
NCT00010088Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile DuctInterventionalPhase 2Unknown statusFrancePancreatic CancerInfos
NCT00010088Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile DuctInterventionalPhase 2Unknown statusLuxembourgPancreatic CancerInfos
NCT00010270LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal CancerInterventionalPhase 1Unknown statusGermanyColorectal CancerInfos
NCT00010270LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal CancerInterventionalPhase 1Unknown statusGermanyEsophageal CancerInfos
NCT00010270LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal CancerInterventionalPhase 1Unknown statusGermanyGastric CancerInfos
NCT00010270LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal CancerInterventionalPhase 1Unknown statusGermanyPancreatic CancerInfos
NCT00024375DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusGermanyPancreatic CancerInfos
NCT00024375DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusNetherlandsPancreatic CancerInfos
NCT00024375DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusUnited KingdomPancreatic CancerInfos
NCT00033319Aspirin and/or Folic Acid in Preventing Recurrent Colorectal PolypsInterventionalNot ApplicableUnknown statusUnited KingdomColorectal CancerInfos
NCT00041262Combination Chemotherapy in Treating Patients With Esophageal CancerInterventionalPhase 3Unknown statusUnited KingdomEsophageal CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusGermanyFallopian Tube CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusGermanyOvarian CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusGermanyPrimary Peritoneal Cavity CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusHungaryFallopian Tube CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusHungaryOvarian CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusHungaryPrimary Peritoneal Cavity CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusNetherlandsFallopian Tube CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusNetherlandsOvarian CancerInfos
NCT00045461Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerInterventionalPhase 2/Phase 3Unknown statusNetherlandsPrimary Peritoneal Cavity CancerInfos
NCT00046995Combination Chemotherapy in Treating Patients With Colon CancerInterventionalPhase 3Unknown statusBelgiumColorectal CancerInfos
NCT00070005J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal AdenocarcinomaInterventionalPhase 3Unknown statusNetherlandsColorectal CancerInfos
NCT00072553Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal CancerInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00075452Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic AdenocarcinomaInterventionalPhase 3Unknown statusFrancePancreatic CancerInfos
NCT00075465Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the StomachInterventionalPhase 2Unknown statusFranceGastric CancerInfos
NCT00075556Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal AdenocarcinomaInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00075595Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal CancerInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00075738Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal CancerInterventionalPhase 2Unknown statusFranceEsophageal CancerInfos
NCT00077389Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk HepatoblastomaInterventionalPhase 2Unknown statusFranceLiver CancerInfos
NCT00077389Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk HepatoblastomaInterventionalPhase 2Unknown statusIrelandLiver CancerInfos
NCT00077389Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk HepatoblastomaInterventionalPhase 2Unknown statusNetherlandsLiver CancerInfos
NCT00077389Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk HepatoblastomaInterventionalPhase 2Unknown statusUnited KingdomLiver CancerInfos
NCT00079027Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)InterventionalPhase 3Unknown statusUnited KingdomLiver CancerInfos
NCT00091312Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerInterventionalPhase 3Unknown statusFranceColorectal CancerInfos
NCT00091312Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerInterventionalPhase 3Unknown statusGermanyColorectal CancerInfos
NCT00091312Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerInterventionalPhase 3Unknown statusItalyColorectal CancerInfos
NCT00091312Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerInterventionalPhase 3Unknown statusPortugalColorectal CancerInfos
NCT00091312Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerInterventionalPhase 3Unknown statusSpainColorectal CancerInfos
NCT00108875Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical CancerInterventionalPhase 1/Phase 2Unknown statusGermanyColon CancerInfos
NCT00108875Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical CancerInterventionalPhase 1/Phase 2Unknown statusGermanyPancreatic CancerInfos
NCT00114829Preoperative Assessment of Colon TumorInterventionalPhase 4Unknown statusDenmarkColorectal CancerInfos
NCT00119912NORCCAP: Norwegian Colorectal Cancer Prevention TrialInterventionalNot ApplicableActive but recruitment closedNorwayAdenomaInfos
NCT00119912NORCCAP: Norwegian Colorectal Cancer Prevention TrialInterventionalNot ApplicableActive but recruitment closedNorwayColorectal CancerInfos
NCT00121914Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin AloneInterventionalPhase 3Unknown statusAustriaCarcinoma, HepatocellularInfos
NCT00134758Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) PatientsInterventionalPhase 2/Phase 3Unknown statusFranceAdenomatous Polyposis Coli, FamilialInfos
NCT00141466Implementation of a New Strategy to Identify HNPCC PatientsInterventionalNot ApplicableUnknown statusNetherlandsHereditary Nonpolyposis Colorectal CancerInfos
NCT00162669Bevacizumab in Advanced Hepatocellular CarcinomaInterventionalPhase 2Unknown statusFranceHepatocellular CarcinomaInfos
NCT00182715Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerInterventionalPhase 3Unknown statusIrelandColorectal CancerInfos
NCT00182715Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerInterventionalPhase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT00188110Performance of the Water-Enema Computed Tomography (WE-CT)InterventionalNot ApplicableUnknown statusFranceColon CancerInfos
NCT00189683Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to ChemotherapyInterventionalPhase 3Unknown statusFranceColorectal CancerInfos
NCT00215722XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal CancerInterventionalPhase 2Unknown statusPortugalColorectal CarcinomaInfos
NCT00220077Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal CancerInterventionalNot ApplicableUnknown statusUnited KingdomOesophageal CancerInfos
NCT00220246Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal CancerObservationalN/AUnknown statusNetherlandsColorectal NeoplasmsInfos
NCT00225641Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal CancerInterventionalNot ApplicableUnknown statusDenmarkColorectal CancerInfos
NCT00250328Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-ColectomyInterventionalPhase 1Unknown statusIsraelColon CancerInfos
NCT00253812Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard EndoscopyInterventionalNot ApplicableUnknown statusUnited KingdomFamilial Adenomatous PolyposisInfos
NCT00259532Three New Methods for Diagnosing Pancreas CancerInterventionalNot ApplicableUnknown statusDenmarkPancreas CancerInfos
NCT00268411Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic CancerInterventionalPhase 3Unknown statusFrancePancreatic CancerInfos
NCT00274872Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By SurgeryInterventionalPhase 2/Phase 3Unknown statusFranceColorectal CancerInfos
NCT00274885Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerInterventionalPhase 4Unknown statusFranceCancerInfos
NCT00275119Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By SurgeryInterventionalPhase 2Unknown statusFrancePancreatic CancerInfos
NCT00276705Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver CancerInterventionalPhase 2Unknown statusIrelandLiver CancerInfos
NCT00276705Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver CancerInterventionalPhase 2Unknown statusUnited KingdomLiver CancerInfos
NCT00287976Irinotecan in Treating Young Patients With Refractory or Recurrent HepatoblastomaInterventionalPhase 2Unknown statusIrelandLiver CancerInfos
NCT00287976Irinotecan in Treating Young Patients With Refractory or Recurrent HepatoblastomaInterventionalPhase 2Unknown statusNetherlandsLiver CancerInfos
NCT00287976Irinotecan in Treating Young Patients With Refractory or Recurrent HepatoblastomaInterventionalPhase 2Unknown statusUnited KingdomLiver CancerInfos
NCT00299299Modelling Internal Hepatic Movement With an External Abdominal MarkerObservationalN/AUnknown statusUnited KingdomPatients With Liver Metastases From Colorectal CancerInfos
NCT00303745Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By SurgeryInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00305838CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving TamoxifenInterventionalPhase 2Unknown statusUnited KingdomFallopian Tube CancerInfos
NCT00305838CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving TamoxifenInterventionalPhase 2Unknown statusUnited KingdomOvarian CancerInfos
NCT00305838CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving TamoxifenInterventionalPhase 2Unknown statusUnited KingdomPrimary Peritoneal Cavity CancerInfos
NCT00319007Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous PolyposisInterventionalPhase 2Unknown statusNetherlandsAdenomatous Polyposis ColiInfos
NCT0034628132P BioSiliconTM in Addition to Gemcitabine in Pancreatic CancerInterventionalPhase 2Unknown statusUnited KingdomPancreatic CancerInfos
NCT00356161HAI Via Interventionally Implanted Port Catheter SystemsInterventionalPhase 2Unknown statusGermanyColorectal CancerInfos
NCT00356161HAI Via Interventionally Implanted Port Catheter SystemsInterventionalPhase 2Unknown statusGermanyHepatocellular CarcinomaInfos
NCT00357682A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaInterventionalPhase 3Unknown statusUnited KingdomEsophageal CancerInfos
NCT00383695Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal CancerInterventionalPhase 2Unknown statusSpainColorectal CancerInfos
NCT00383695Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal CancerInterventionalPhase 2Unknown statusSwedenColorectal CancerInfos
NCT00383695Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal CancerInterventionalPhase 2Unknown statusUnited KingdomColorectal CancerInfos
NCT00392470Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal CancerInterventionalPhase 1Unknown statusSwitzerlandColorectal CancerInfos
NCT00407186Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)InterventionalPhase 3Active but recruitment closedNetherlandsGastric CancerInfos
NCT00411112Sentinel Node in Colon CancerInterventionalNot ApplicableUnknown statusFranceColon CancerInfos
NCT00420394Perioperative Chemoradiotherapy for Potentially Resectable Gastric CancerInterventionalPhase 2Unknown statusIsraelStomach NeoplasmsInfos
NCT00425425Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal CancerInterventionalPhase 1/Phase 2Unknown statusGermanyEsophageal CancerInfos
NCT004339275-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)InterventionalPhase 3Unknown statusGermanyColorectal CancerInfos
NCT004339275-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)InterventionalPhase 3Unknown statusGermanyNeoplasm MetastasisInfos
NCT00435097Computer Assisted Early Detection of Liver Metastases From fMRI MapsObservationalN/AUnknown statusIsraelMetastatic Colorectal CancerInfos
NCT00438737Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal CancerInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00438737Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal CancerInterventionalPhase 2Unknown statusFranceMetastatic CancerInfos
NCT00440167Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of CapecitabineInterventionalPhase 3Unknown statusGermanyPancreatic CancerInfos
NCT00442637Maintenance Treatment Versus Observation After Induction in Advanced Colorectal CarcinomaInterventionalPhase 3Unknown statusNetherlandsColorectal Cancer MetastaticInfos
NCT00450203Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric CancerInterventionalPhase 2/Phase 3Unknown statusUnited KingdomOesophagogastric CancerInfos
NCT00450788Esophageal Cancer in Northeastern IranObservationalN/AActive but recruitment closedFranceEsophageal CancerInfos
NCT00450788Esophageal Cancer in Northeastern IranObservationalN/AActive but recruitment closedFranceGI DiseaseInfos
NCT00468416Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior ResectionInterventionalPhase 2Unknown statusIsraelColorectal CancerInfos
NCT00474734Intravascular Ultrasound for Hepatocellular Carcinoma StagingObservationalN/AUnknown statusSwitzerlandHepatocellular CarcinomaInfos
NCT00478946A Study of Picoplatin in Colorectal CancerInterventionalPhase 1/Phase 2Unknown statusRussian FederationColorectal CancerInfos
NCT00482222Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal CancerInterventionalPhase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT00482222Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal CancerInterventionalPhase 3Unknown statusUnited KingdomMetastatic CancerInfos
NCT00486460Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic CancerInterventionalPhase 3Unknown statusIsraelPancreatic CancerInfos
NCT00501176Preoperative Stent StudyInterventionalNot ApplicableUnknown statusSwedenPancreas CancerInfos
NCT00509561Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal CancerInterventionalPhase 2/Phase 3Unknown statusUnited KingdomEsophageal CancerInfos
NCT00513266Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by SurgeryInterventionalPhase 2Unknown statusSwitzerlandColorectal CancerInfos
NCT00513266Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by SurgeryInterventionalPhase 2Unknown statusSwitzerlandMetastatic CancerInfos
NCT00514930Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the LiverInterventionalPhase 1/Phase 2Unknown statusGreeceLiver CancerInfos
NCT00516347Studying Genes for Barrett's Esophagus in Brothers and SistersObservationalN/AUnknown statusUnited KingdomEsophageal CancerInfos
NCT00541021Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 3Unknown statusFrancePancreatic CancerInfos
NCT00544011Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00551057Expression of Inflammatory Proteins in Pancreatic CancerObservationalN/AUnknown statusSwitzerlandPancreatic NeoplasmsInfos
NCT00559858Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast CancerInterventionalPhase 3Unknown statusUnited KingdomBreast CancerInfos
NCT00559858Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast CancerInterventionalPhase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT00559858Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast CancerInterventionalPhase 3Unknown statusUnited KingdomPalmar-plantar ErythrodysesthesiaInfos
NCT00560365Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal CancerObservationalN/AUnknown statusUnited KingdomColorectal CancerInfos
NCT00582257Early Onset and Familial Gastric Cancer RegistryObservationalN/AActive but recruitment closedIsraelGastric CancerInfos
NCT00628368Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal CancerInterventionalNot ApplicableUnknown statusFranceColorectal CancerInfos
NCT00628368Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal CancerInterventionalNot ApplicableUnknown statusFranceEsophageal CancerInfos
NCT00647530Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by SurgeryInterventionalPhase 2/Phase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT00669370Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric CancerInterventionalPhase 2Unknown statusFinlandStomach NeoplasmsInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedEstoniaNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedHungaryNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedIsraelNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedItalyNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedNetherlandsNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedPolandNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedRussian FederationNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedTurkeyNeoplasms, Gastrointestinal TractInfos
NCT00680901LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibInterventionalPhase 3Active but recruitment closedUkraineNeoplasms, Gastrointestinal TractInfos
NCT00690300Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic CancerInterventionalPhase 2Unknown statusGermanyPancreas NeoplasmsInfos
NCT00693290Improving Outcomes for Patients Requiring Oral Bowel Preparation for ColonoscopyInterventionalNot ApplicableUnknown statusUnited KingdomColorectal CancerInfos
NCT00710632Screening to Predict Weight Loss in Patients With CancerInterventionalNot ApplicableUnknown statusUnited KingdomGastrointestinal CancerInfos
NCT00722228Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic TumorsInterventionalPhase 1/Phase 2Unknown statusIsraelColorectal CancerInfos
NCT00722228Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic TumorsInterventionalPhase 1/Phase 2Unknown statusIsraelGastric CancerInfos
NCT00756509Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibInterventionalPhase 4Active but recruitment closedFinlandGastrointestinal Stromal TumorsInfos
NCT00756509Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibInterventionalPhase 4Active but recruitment closedFranceGastrointestinal Stromal TumorsInfos
NCT00756509Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibInterventionalPhase 4Active but recruitment closedGermanyGastrointestinal Stromal TumorsInfos
NCT00756509Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibInterventionalPhase 4Active but recruitment closedItalyGastrointestinal Stromal TumorsInfos
NCT00756509Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibInterventionalPhase 4Active but recruitment closedSpainGastrointestinal Stromal TumorsInfos
NCT00757614Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United KingdomObservationalN/AUnknown statusUnited KingdomEsophageal CancerInfos
NCT00757614Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United KingdomObservationalN/AUnknown statusUnited KingdomPancreatic CancerInfos
NCT00757965Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United KingdomObservationalN/AUnknown statusUnited KingdomColorectal CancerInfos
NCT00758381Metastatic Advanced Pancreas SorafenibInterventionalPhase 2Unknown statusItalyLocally Advanced Pancreatic CancerInfos
NCT00777478Capiri-sutent Phase-1 in Advanced Colo-rectal CancerInterventionalPhase 1Unknown statusNetherlandsColorectal CancerInfos
NCT00777504Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsInterventionalPhase 4Unknown statusNetherlandsGastrointestinal Stromal TumorInfos
NCT00790140Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer SurgeryInterventionalPhase 4Unknown statusIrelandEsophageal CancerInfos
NCT00797251Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger CompressionObservationalN/AUnknown statusItalyHepatocellular CarcinomaInfos
NCT00797485Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By SurgeryInterventionalPhase 3Unknown statusItalyColorectal CancerInfos
NCT00813696Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic CancerInterventionalPhase 3Unknown statusItalyPancreatic CancerInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFranceAnxiety DisorderInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFranceCognitive/Functional EffectsInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFranceColorectal CancerInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFranceDepressionInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFranceExcerciseInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFranceFatigueInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFrancePsychosocial Effects of Cancer and Its TreatmentInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openFranceSleep DisordersInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomAnxiety DisorderInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomCognitive/Functional EffectsInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomColorectal CancerInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomDepressionInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomExcerciseInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomFatigueInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomPsychosocial Effects of Cancer and Its TreatmentInfos
NCT00819208Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon CancerInterventionalNot ApplicableRecruitment openUnited KingdomSleep DisordersInfos
NCT00821912TaxXel: Taxotere and Xeloda in Esophageal CancerInterventionalPhase 1/Phase 2Unknown statusNorwayCancer of the EsophagusInfos
NCT00821912TaxXel: Taxotere and Xeloda in Esophageal CancerInterventionalPhase 1/Phase 2Unknown statusNorwayGastric Cardia CarcinomaInfos
NCT00821912TaxXel: Taxotere and Xeloda in Esophageal CancerInterventionalPhase 1/Phase 2Unknown statusSwedenCancer of the EsophagusInfos
NCT00821912TaxXel: Taxotere and Xeloda in Esophageal CancerInterventionalPhase 1/Phase 2Unknown statusSwedenGastric Cardia CarcinomaInfos
NCT00825110SS-GCC1- Screening Study of Genetic Changes in Colorectal CancerObservationalN/AUnknown statusUnited KingdomColorectal CancerInfos
NCT00838656Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerInterventionalPhase 2Unknown statusUnited KingdomFallopian Tube CancerInfos
NCT00838656Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerInterventionalPhase 2Unknown statusUnited KingdomOvarian CancerInfos
NCT00838656Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerInterventionalPhase 2Unknown statusUnited KingdomPrimary Peritoneal Cavity CancerInfos
NCT00845884Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric CancerInterventionalPhase 1/Phase 2Unknown statusIsraelAdvanced Gastric CancerInfos
NCT00848952Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on CirrhosisInterventionalNot ApplicableUnknown statusFranceHepatocellular CarcinomaInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusBelgiumHepatic LesionsInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusBelgiumLiver MetastasesInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusBelgiumMetastatic Colorectal CancerInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusFranceHepatic LesionsInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusFranceLiver MetastasesInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusFranceMetastatic Colorectal CancerInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusItalyHepatic LesionsInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusItalyLiver MetastasesInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusItalyMetastatic Colorectal CancerInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusPortugalHepatic LesionsInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusPortugalLiver MetastasesInfos
NCT00852228Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of ChemotherapyInterventionalPhase 2Unknown statusPortugalMetastatic Colorectal CancerInfos
NCT00860691Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon CancerInterventionalNot ApplicableUnknown statusCroatiaColonic NeoplasmsInfos
NCT00865982Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal CancerInterventionalPhase 2Unknown statusGermanyEsophageal CancerInfos
NCT00865982Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal CancerInterventionalPhase 2Unknown statusGermanyGastric CancerInfos
NCT00883792The Northern-European Initiative on Colorectal CancerInterventionalPhase 3Active but recruitment closedIcelandColorectal CancerInfos
NCT00883792The Northern-European Initiative on Colorectal CancerInterventionalPhase 3Active but recruitment closedLatviaColorectal CancerInfos
NCT00883792The Northern-European Initiative on Colorectal CancerInterventionalPhase 3Active but recruitment closedNetherlandsColorectal CancerInfos
NCT00883792The Northern-European Initiative on Colorectal CancerInterventionalPhase 3Active but recruitment closedNorwayColorectal CancerInfos
NCT00883792The Northern-European Initiative on Colorectal CancerInterventionalPhase 3Active but recruitment closedPolandColorectal CancerInfos
NCT00883792The Northern-European Initiative on Colorectal CancerInterventionalPhase 3Active but recruitment closedSwedenColorectal CancerInfos
NCT00884767Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving OxaliplatinInterventionalPhase 2Unknown statusFranceChemotherapeutic Agent ToxicityInfos
NCT00884767Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving OxaliplatinInterventionalPhase 2Unknown statusFranceColorectal CancerInfos
NCT00884767Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving OxaliplatinInterventionalPhase 2Unknown statusFranceNeurotoxicityInfos
NCT00888797β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer RecurrenceInterventionalPhase 3Unknown statusIsraelColorectal NeoplasmsInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusAustriaColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusDenmarkColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusFranceColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusGermanyColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusNetherlandsColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusSpainColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusSwedenColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusSwitzerlandColon CancerInfos
NCT00903565A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrintObservationalN/AUnknown statusUnited KingdomColon CancerInfos
NCT00906997Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus ColonoscopyInterventionalPhase 3Unknown statusSpainColorectal CancerInfos
NCT00906997Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus ColonoscopyInterventionalPhase 3Unknown statusSpainColorectal NeoplasmInfos
NCT00931840A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal CarcinomaInterventionalPhase 2Unknown statusIsraelMetastatic Colorectal CancerInfos
NCT00931840A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal CarcinomaInterventionalPhase 2Unknown statusNetherlandsMetastatic Colorectal CancerInfos
NCT00931840A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal CarcinomaInterventionalPhase 2Unknown statusUnited KingdomMetastatic Colorectal CancerInfos
NCT00934505Predictive Value of Pet Scan With Fdg Performed During Irradiation in Patients Treated for Oesaphagus CarcinomaObservationalN/AUnknown statusFranceOesophageal CancerInfos
NCT00947102Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic CancerObservationalN/AUnknown statusSloveniaPancreatic Tubular AdenocarcinomaInfos
NCT00958737Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon CancerInterventionalPhase 3Active but recruitment closedFranceColorectal CancerInfos
NCT00963092Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction CancerObservationalN/AUnknown statusUnited KingdomAdenocarcinoma of the Gastroesophageal JunctionInfos
NCT00963092Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction CancerObservationalN/AUnknown statusUnited KingdomEsophageal CancerInfos
NCT00963092Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction CancerObservationalN/AUnknown statusUnited KingdomGastric CancerInfos
NCT00963352Colon Cancer Prognosis After Radical SurgeryObservationalN/AUnknown statusNorwayColon CancerInfos
NCT00964171Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusFrancePancreatic CancerInfos
NCT00964457Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type PatientsInterventionalPhase 2Unknown statusDenmarkRectum CancerInfos
NCT00973869Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal SurgeryInterventionalPhase 1Unknown statusUnited KingdomColorectal CancerInfos
NCT00987857Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett EsophagusInterventionalNot ApplicableUnknown statusUnited KingdomEsophageal CancerInfos
NCT00994864Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon CancerInterventionalNot ApplicableActive but recruitment closedBelgiumColon CancerInfos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumPancreatic Acinar Cell CarcinomaInfos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumPancreatic Ductal AdenocarcinomaInfos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumPancreatic Intraductal Papillary-Mucinous NeoplasmInfos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumStage IA Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumStage IB Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumStage IIA Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumStage IIB Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumStage II Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedBelgiumStage I Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelPancreatic Acinar Cell CarcinomaInfos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelPancreatic Ductal AdenocarcinomaInfos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelPancreatic Intraductal Papillary-Mucinous NeoplasmInfos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelStage IA Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelStage IB Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelStage IIA Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelStage IIB Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelStage II Pancreatic Cancer AJCC v6 and v7Infos
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryInterventionalPhase 3Active but recruitment closedIsraelStage I Pancreatic Cancer AJCC v6 and v7Infos
NCT01037049Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 WeeksInterventionalPhase 2Unknown statusCyprusDigestive System NeoplasmsInfos
NCT01037049Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 WeeksInterventionalPhase 2Unknown statusUnited KingdomDigestive System NeoplasmsInfos
NCT01038154Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal CancerInterventionalPhase 4Unknown statusSpainEsophageal CancerInfos
NCT01038154Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal CancerInterventionalPhase 4Unknown statusSpainStomach CancerInfos
NCT01044511Quality of Life With Esophageal Stent TrialInterventionalNot ApplicableUnknown statusDenmarkEsophageal CancerInfos
NCT01048216Partial Liver Radiotherapy for Unresectable Liver MetastasesInterventionalNot ApplicableUnknown statusUnited KingdomMetastatic Colorectal Liver CancerInfos
NCT01056796Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27InterventionalPhase 2Unknown statusBelgiumColorectal CancerInfos
NCT01062334Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum CancerInterventionalNot ApplicableUnknown statusDenmarkCancerInfos
NCT01064375Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal CancerInterventionalPhase 1/Phase 2Unknown statusSwedenColorectal CancerInfos
NCT01067053Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.InterventionalPhase 2Unknown statusSpainMetastatic Colorectal CancerInfos
NCT01071824Comparison of Limb Size of Transverse Coloplasty PouchInterventionalNot ApplicableRecruitment openSwitzerlandColon CancerInfos
NCT01073358Resection of Colorectal Liver Metastases With or Without Routine Hilar LymphadenectomyInterventionalNot ApplicableUnknown statusGermanyColorectal CancerInfos
NCT01087268Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic CancerInterventionalPhase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT01097265Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by SurgeryInterventionalPhase 2/Phase 3Unknown statusNetherlandsColorectal CancerInfos
NCT01106261A Randomised Trial of Pulmonary Metastasectomy in Colorectal CancerInterventionalNot ApplicableUnknown statusItalyColorectal CancerInfos
NCT01106261A Randomised Trial of Pulmonary Metastasectomy in Colorectal CancerInterventionalNot ApplicableUnknown statusItalyPulmonary MetastasesInfos
NCT01106261A Randomised Trial of Pulmonary Metastasectomy in Colorectal CancerInterventionalNot ApplicableUnknown statusSerbiaColorectal CancerInfos
NCT01106261A Randomised Trial of Pulmonary Metastasectomy in Colorectal CancerInterventionalNot ApplicableUnknown statusSerbiaPulmonary MetastasesInfos
NCT01106261A Randomised Trial of Pulmonary Metastasectomy in Colorectal CancerInterventionalNot ApplicableUnknown statusUnited KingdomColorectal CancerInfos
NCT01106261A Randomised Trial of Pulmonary Metastasectomy in Colorectal CancerInterventionalNot ApplicableUnknown statusUnited KingdomPulmonary MetastasesInfos
NCT01110785Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal CancerInterventionalPhase 2Unknown statusNetherlandsColorectal CancerInfos
NCT01110798J-Pouch Colorectal Anastomosis or Straight Colorectal Anastomosis in Treating Patients With Rectal Cancer Who Have Undergone Surgery to Remove the TumorInterventionalNot ApplicableUnknown statusItalyColorectal CancerInfos
NCT01116804Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)InterventionalPhase 1Unknown statusBelgiumPrimary Liver CancerInfos
NCT01144195A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line ChemotherapyInterventionalPhase 2Unknown statusSpainMetastatic Colorectal CancerInfos
NCT01160419Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric CancerInterventionalPhase 2Unknown statusGermanyGastric CancerInfos
NCT01167374Carbon Ion Radiotherapy for Hepatocellular CarcinomaInterventionalNot ApplicableActive but recruitment closedGermanyHepatocellular CarcinomaInfos
NCT01182246AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic CancerInterventionalPhase 1/Phase 2Unknown statusSwedenAdenocarcinomaInfos
NCT01182272Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by SurgeryInterventionalPhase 2Unknown statusFranceLiver CancerInfos
NCT01183156Re-invitation to Screening Colonoscopy: a Randomized StudyInterventionalNot ApplicableUnknown statusPolandColorectal CancerInfos
NCT01190462Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal CancerInterventionalPhase 2Unknown statusNetherlandsColorectal CancerInfos
NCT01214681Chemoprevention of Colorectal Cancer: the Role of Non-digestible CarbohydratesInterventionalNot ApplicableUnknown statusUnited KingdomColorectal CancerInfos
NCT01226394Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal PatientsInterventionalPhase 3Unknown statusFranceColorectal Cancer With a Resected Minimal Synchronous PCInfos
NCT01230697Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)ObservationalN/AUnknown statusItalyKidney CancerInfos
NCT01230697Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)ObservationalN/AUnknown statusItalyLiver CancerInfos
NCT01234246Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners.ObservationalN/AUnknown statusNetherlandsColorectal Cancer Patients and Their PartnersInfos
NCT01236989Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCCInterventionalNot ApplicableUnknown statusItalyPatients Affected by Hepatocellular CarcinomaInfos
NCT01249638Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRCInterventionalPhase 3Unknown statusGermanyColorectal Cancer MetastaticInfos
NCT01254591Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck CancerInterventionalNot ApplicableUnknown statusUnited KingdomBreast CancerInfos
NCT01254591Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck CancerInterventionalNot ApplicableUnknown statusUnited KingdomColorectal CancerInfos
NCT01254591Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck CancerInterventionalNot ApplicableUnknown statusUnited KingdomEsophageal CancerInfos
NCT01254591Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck CancerInterventionalNot ApplicableUnknown statusUnited KingdomHead and Neck CancerInfos
NCT01254591Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck CancerInterventionalNot ApplicableUnknown statusUnited KingdomLung CancerInfos
NCT01272557Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II TrialInterventionalPhase 2Unknown statusGermanyLiver CarcinomaInfos
NCT01276574Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CTObservationalN/AActive but recruitment closedFinlandPeritoneal CancerInfos
NCT01279278Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?InterventionalNot ApplicableUnknown statusFranceColorectal CancerInfos
NCT01279330Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?InterventionalNot ApplicableUnknown statusFranceColorectal CancerInfos
NCT01286064Colorectal Cancer Detection by Means of Optical FluoroscopyInterventionalNot ApplicableUnknown statusItalyColorectal CancerInfos
NCT01292369Breath Testing for Breast and Colon Cancer Diagnosis- NaNose StudyObservationalN/AUnknown statusIsraelBreast CancerInfos
NCT01292369Breath Testing for Breast and Colon Cancer Diagnosis- NaNose StudyObservationalN/AUnknown statusIsraelColon CancerInfos
NCT01292681Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal CancerInterventionalNot ApplicableUnknown statusNetherlandsColorectal CancerInfos
NCT01308086Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon CancerInterventionalPhase 3Unknown statusGreeceCRCInfos
NCT01315990FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular ExanthemaInterventionalPhase 4Unknown statusGermanyColorectal Cancer MetastaticInfos
NCT01320319Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery PatientsInterventionalPhase 2/Phase 3Unknown statusUnited KingdomColorectal CancerInfos
NCT01322477Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment EfficiencyObservationalN/AUnknown statusIsraelHepatocellular CarcinomaInfos
NCT01324076Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By SurgeryInterventionalPhase 3Unknown statusUnited KingdomLiver CancerInfos
NCT01324856Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic DuodenopancreatectomyInterventionalPhase 1Unknown statusSerbiaPancreatic CancerInfos
NCT01328171FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)InterventionalPhase 2Active but recruitment closedGermanyMetastatic Colorectal CancerInfos
NCT01330186Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- ChemotherapyObservationalN/AUnknown statusDenmarkAnal CancerInfos
NCT01351103A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsInterventionalPhase 1Recruitment openNetherlandsBRAF Mutant Colorectal CancerInfos
NCT01351103A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsInterventionalPhase 1Recruitment openNetherlandsPancreatic CancerInfos
NCT01351103A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsInterventionalPhase 1Recruitment openSpainBRAF Mutant Colorectal CancerInfos
NCT01351103A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsInterventionalPhase 1Recruitment openSpainPancreatic CancerInfos
NCT01351714Safe D3 Right Hemicolectomy for Cancer Through Multidetector Computed Tomography (MDCT) AngioInterventionalNot ApplicableRecruitment openNorwayColon CancerInfos
NCT01359397Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric CancerInterventionalPhase 2Active but recruitment closedNetherlandsAdenocarcinoma of the Gastro-oesophageal JunctionInfos
NCT01359397Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric CancerInterventionalPhase 2Active but recruitment closedNetherlandsMetastatic Gastric CancerInfos
NCT01363739Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus BevacizumabObservationalN/AUnknown statusItalyMetastatic Colorectal CancerInfos
NCT01372735Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic CancerInterventionalPhase 1/Phase 2Unknown statusGermanyPancreatic NeoplasmsInfos
NCT01377220Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular CarcinomaInterventionalPhase 2Unknown statusFranceHepatocellular CarcinomaInfos
NCT01380262Pre-emptive Low-dose Doxycycline During Anti-EGFR TreatmentObservationalN/AUnknown statusPolandColorectal CancerInfos
NCT01384994Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type PatientsInterventionalPhase 2Unknown statusGermanyAfter Resection of Liver MetastasesInfos
NCT01384994Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type PatientsInterventionalPhase 2Unknown statusGermanyColorectal CancerInfos
NCT01384994Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type PatientsInterventionalPhase 2Unknown statusGermanyKRAS WildtypeInfos
NCT01394120Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic CancerInterventionalPhase 2Unknown statusSpainCarcinoma, Pancreatic DuctalInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusBelgiumFallopian Tube CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusBelgiumOvarian CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusBelgiumPrimary Peritoneal Cavity CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusNetherlandsFallopian Tube CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusNetherlandsOvarian CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusNetherlandsPrimary Peritoneal Cavity CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusSpainFallopian Tube CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusSpainOvarian CancerInfos
NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerInterventionalPhase 1/Phase 2Unknown statusSpainPrimary Peritoneal Cavity CancerInfos
NCT01410760PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver MetastasesInterventionalEarly Phase 1Unknown statusUnited KingdomMetastatic Colorectal CancerInfos
NCT01436656A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaInterventionalPhase 1Active but recruitment closedFranceMelanoma and Metastatic Colorectal CancerInfos
NCT01436656A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaInterventionalPhase 1Active but recruitment closedNorwayMelanoma and Metastatic Colorectal CancerInfos
NCT01436656A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaInterventionalPhase 1Active but recruitment closedSpainMelanoma and Metastatic Colorectal CancerInfos
NCT01436656A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaInterventionalPhase 1Active but recruitment closedSwitzerlandMelanoma and Metastatic Colorectal CancerInfos
NCT01441453Transient Elastography in Hepatectomy for Hepatocellular CarcinomaInterventionalNot ApplicableUnknown statusItalyHepatocellular CarcinomaInfos
NCT01441453Transient Elastography in Hepatectomy for Hepatocellular CarcinomaInterventionalNot ApplicableUnknown statusItalySurgeryInfos
NCT01442324Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & CholangiocarcinomaInterventionalNot ApplicableUnknown statusItalyCholangiocarcinomaInfos
NCT01442324Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & CholangiocarcinomaInterventionalNot ApplicableUnknown statusItalyMetastatic Liver CancerInfos
NCT01442324Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & CholangiocarcinomaInterventionalNot ApplicableUnknown statusItalyNeoplasm MetastasisInfos
NCT01444755The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric CancerObservationalN/AUnknown statusTurkeyGastric CancerInfos
NCT01448655Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)ObservationalN/AUnknown statusAustriaColorectal CancerInfos
NCT01448655Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)ObservationalN/AUnknown statusGermanyColorectal CancerInfos
NCT01448668Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)ObservationalN/AUnknown statusAustriaPancreas CancerInfos
NCT01448668Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)ObservationalN/AUnknown statusGermanyPancreas CancerInfos
NCT01456455Gastric Cancer Metastasized to the Central Nervous System (CNS)ObservationalN/AUnknown statusSwitzerlandGastric CancerInfos
NCT01458353Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon CancerInterventionalPhase 3Unknown statusSpainIntra-abdominal AbscessInfos
NCT01458353Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon CancerInterventionalPhase 3Unknown statusSpainPeritoneal Contamination After Ileocolonic AnastomosisInfos
NCT01458353Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon CancerInterventionalPhase 3Unknown statusSpainWound InfectionInfos
NCT01470235Hypodontia and Ovarian CancerObservationalN/AUnknown statusDenmarkColon CancerInfos
NCT01479608Liver Transplantation and Colorectal CancerInterventionalPhase 2Recruitment openNorwayColorectal CancerInfos
NCT01479608Liver Transplantation and Colorectal CancerInterventionalPhase 2Recruitment openNorwayLiver MetastasisInfos
NCT01492127Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative TreatmentInterventionalNot ApplicableUnknown statusFranceCirrhosisInfos
NCT01492127Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative TreatmentInterventionalNot ApplicableUnknown statusFranceHepatocellular CarcinomaInfos
NCT01509911A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine TreatmentInterventionalPhase 2Unknown statusIsraelMetastatic Pancreatic CancerInfos
NCT01515787PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing SurgeryInterventionalPhase 2/Phase 3Active but recruitment closedIsraelColorectal CancerInfos
NCT01515787PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing SurgeryInterventionalPhase 2/Phase 3Active but recruitment closedSwitzerlandColorectal CancerInfos
NCT01531595Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal CancerInterventionalPhase 2Recruitment openFinlandMetastatic Colorectal CancerInfos
NCT01531621A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in FinlandObservationalN/ARecruitment openFinlandMetastatic Colorectal CancerInfos
NCT01538550Pilot Study of a National Screening Programme for Bowel Cancer in NorwayInterventionalNot ApplicableActive but recruitment closedNorwayColorectal CancerInfos
NCT01556490Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerInterventionalNot ApplicableActive but recruitment closedBelgiumUnresectable Hepatocellular CarcinomaInfos
NCT01556490Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerInterventionalNot ApplicableActive but recruitment closedFranceUnresectable Hepatocellular CarcinomaInfos
NCT01556490Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerInterventionalNot ApplicableActive but recruitment closedGermanyUnresectable Hepatocellular CarcinomaInfos
NCT01556490Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerInterventionalNot ApplicableActive but recruitment closedItalyUnresectable Hepatocellular CarcinomaInfos
NCT01556490Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerInterventionalNot ApplicableActive but recruitment closedNetherlandsUnresectable Hepatocellular CarcinomaInfos
NCT01556490Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerInterventionalNot ApplicableActive but recruitment closedSpainUnresectable Hepatocellular CarcinomaInfos
NCT01556490Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerInterventionalNot ApplicableActive but recruitment closedUnited KingdomUnresectable Hepatocellular CarcinomaInfos
NCT01563133Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the PancreasInterventionalNot ApplicableUnknown statusFrancePancreatic CancerInfos
NCT01570010Effect of Norwegian Food Based Dietary Guidelines on Chronic Diseases in CRC SurvivorsInterventionalNot ApplicableActive but recruitment closedNorwayColorectal CancerInfos
NCT01573468Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric CancerInterventionalPhase 2Unknown statusGermanyGastric CarcinomaInfos
NCT01585805Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 2Active but recruitment closedIsraelLocally Advanced Pancreatic AdenocarcinomaInfos
NCT01585805Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 2Active but recruitment closedIsraelMetastatic Pancreatic AdenocarcinomaInfos
NCT01585805Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 2Active but recruitment closedIsraelRecurrent Pancreatic CarcinomaInfos
NCT01585805Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 2Active but recruitment closedIsraelStage III Pancreatic Cancer AJCC v6 and v7Infos
NCT01585805Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerInterventionalPhase 2Active but recruitment closedIsraelStage IV Pancreatic Cancer AJCC v6 and v7Infos
NCT01589146ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.InterventionalPhase 3Unknown statusItalyFrom Surgery in the Two Study Groups.Infos
NCT01589146ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.InterventionalPhase 3Unknown statusItalyProphylaxis Given for 8±2 Days After Planned LaparoscopicInfos
NCT01589146ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.InterventionalPhase 3Unknown statusItalySafety of Extended 4-week Heparin Prophylaxis Compared toInfos
NCT01589146ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.InterventionalPhase 3Unknown statusItalySurgery for Colorectal Cancer.Infos
NCT01589146ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.InterventionalPhase 3Unknown statusItalyThe Clinical Benefit Will be Evaluated as the Difference inInfos
NCT01589146ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.InterventionalPhase 3Unknown statusItalythe Incidence of VTE or VTE-related Death Occurring Within 30 DaysInfos
NCT01589146ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.InterventionalPhase 3Unknown statusItalyThe Primary Study Objective is to Assess the Efficacy andInfos
NCT01601808Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic CarcinomaInterventionalPhase 2Unknown statusUnited KingdomPancreatic CancerInfos
NCT01606098The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal CancerInterventionalPhase 3Active but recruitment closedDenmarkColon CancerInfos
NCT01606098The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal CancerInterventionalPhase 3Active but recruitment closedDenmarkPrimary TumourInfos
NCT01606098The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal CancerInterventionalPhase 3Active but recruitment closedDenmarkRectal CancerInfos
NCT01606098The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal CancerInterventionalPhase 3Active but recruitment closedNetherlandsColon CancerInfos
NCT01606098The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal CancerInterventionalPhase 3Active but recruitment closedNetherlandsPrimary TumourInfos
NCT01606098The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal CancerInterventionalPhase 3Active but recruitment closedNetherlandsRectal CancerInfos
NCT01626963Single-port Versus Conventional Laparoscopic Colorectal SurgeryInterventionalPhase 1/Phase 2Unknown statusUnited KingdomColorectal CancerInfos
NCT01628211Second Look Laparoscopy in Colorectal CancerInterventionalPhase 2Recruitment openItalyColorectal CancerInfos
NCT01639326Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1InterventionalPhase 2Unknown statusSpainMetastatic Colorectal CancerInfos
NCT01641003Isolation and Characterization of Cancer Stem Cells Using iFP TechniqueObservationalN/AUnknown statusIsraelPancreatic CancerInfos
NCT01642875Early Oral Versus Enteral Nutrition After PancreatoduodenectomyInterventionalPhase 4Unknown statusPolandPancreatic CancerInfos
NCT01651013Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-RasObservationalN/AActive but recruitment closedItalyMetastatic Colorectal CancerInfos
NCT01651026Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal CancerObservationalN/ARecruitment openItalyMetastatic Colorectal CancerInfos
NCT01658878An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerInterventionalPhase 1/Phase 2Active but recruitment closedFranceHepatocellular CarcinomaInfos
NCT01658878An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerInterventionalPhase 1/Phase 2Active but recruitment closedGermanyHepatocellular CarcinomaInfos
NCT01658878An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerInterventionalPhase 1/Phase 2Active but recruitment closedItalyHepatocellular CarcinomaInfos
NCT01658878An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerInterventionalPhase 1/Phase 2Active but recruitment closedSpainHepatocellular CarcinomaInfos
NCT01658878An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerInterventionalPhase 1/Phase 2Active but recruitment closedUnited KingdomHepatocellular CarcinomaInfos
NCT01659502Investigator's Initiated Phase II Study for Pancreatic Cancer PatientsInterventionalPhase 2Unknown statusIsraelPancreatic CancerInfos
NCT01662739Cremona Population-Based Gastric Tumors RegistryObservationalN/AUnknown statusItalyGastric CancerInfos
NCT01673607Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal CancerInterventionalPhase 2Recruitment openFranceResectable Hepatic Metastases of Colorectal CancerInfos
NCT01675258Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic CancersObservationalN/AUnknown statusIsraelColorectal Cancer and Pre-cancer PolypsInfos
NCT01675258Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic CancersObservationalN/AUnknown statusIsraelGastric CancerInfos
NCT01675258Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic CancersObservationalN/AUnknown statusIsraelPancreatic CancerInfos
NCT01675505Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative SurgeryObservationalN/AUnknown statusGreeceAdaptation, PsychologicalInfos
NCT01675505Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative SurgeryObservationalN/AUnknown statusGreeceFunctional InsufficiencyInfos
NCT01675999Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon CancerInterventionalPhase 2Unknown statusFranceColon CancerInfos
NCT01675999Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon CancerInterventionalPhase 2Unknown statusFranceLocally Advanced Malignant NeoplasmInfos
NCT01676259A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic CancerInterventionalPhase 2Recruitment openIsraelPancreatic CancerInfos
NCT01676259A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic CancerInterventionalPhase 2Recruitment openIsraelPancreatic Ductal AdenocarcinomaInfos
NCT01679756INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for CancerInterventionalNot ApplicableUnknown statusItalyColorectal CancerInfos
NCT01686971The Needs of Cancer SurvivorsObservationalN/AUnknown statusIsraelColon Cancer Patients.Infos
NCT01688232The Immunoscore as a Prognostic Marker for Patients With a Colorectal CancerObservationalN/AActive but recruitment closedFranceColorectal CancerInfos
NCT01688232The Immunoscore as a Prognostic Marker for Patients With a Colorectal CancerObservationalN/AActive but recruitment closedFranceSurgical Resection of the Colorectal TumorInfos
NCT01704664Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer PatientsInterventionalNot ApplicableRecruitment openPolandGastric CancerInfos
NCT01706809Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum CancerObservationalN/AUnknown statusDenmarkRectal CancerInfos
NCT01707511The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon SurgeryObservationalN/AUnknown statusTurkeyColorectal CancerInfos
NCT01713218Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic CancerInterventionalEarly Phase 1Unknown statusBelgiumPancreatic Adenocarcinoma ResectableInfos
NCT01715402Optimization of Health Expenditure in Liver SurgeryObservationalN/AUnknown statusFranceHepatocellular CarcinomaInfos
NCT01717196Diagnostic Accuracy of FNA: is Aspiration- Related?InterventionalNot ApplicableUnknown statusItalyPANCREATIC CANCERInfos
NCT01717807C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).ObservationalN/AUnknown statusIsraelPancreatic CancerInfos
NCT01718873Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal CancerInterventionalPhase 3Unknown statusItalyColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusBelgiumAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusBelgiumColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusCyprusAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusCyprusColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusFranceAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusFranceColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusGermanyAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusGermanyColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusGreeceAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusGreeceColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusItalyAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusItalyColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusPolandAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusPolandColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusPortugalAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusPortugalColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusSpainAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusSpainColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusSwedenAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusSwedenColorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusSwitzerlandAdvanced Colorectal CancerInfos
NCT01723969Screening Platform for Clinical Trials in Advanced Colorectal CancerObservationalN/AUnknown statusSwitzerlandColorectal CancerInfos
NCT0172601022-G-Procore Needle for the Diagnosis of SETs of the Upper GI TractInterventionalNot ApplicableUnknown statusGermanySubepithelial Tumors of the Upper Gastrointestinal TractInfos
NCT01726452NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)InterventionalPhase 3Active but recruitment closedDenmarkOesophageal CancerInfos
NCT01726452NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)InterventionalPhase 3Active but recruitment closedFranceOesophageal CancerInfos
NCT01726452NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)InterventionalPhase 3Active but recruitment closedIrelandOesophageal CancerInfos
NCT01726452NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)InterventionalPhase 3Active but recruitment closedSwedenOesophageal CancerInfos
NCT01726452NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)InterventionalPhase 3Active but recruitment closedUnited KingdomOesophageal CancerInfos
NCT01729481Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusGermanyMetastatic Pancreatic AdenocarcinomaInfos
NCT01731366The Effect of Whole Grain on Gut Microbiome and Metabolic HealthInterventionalNot ApplicableUnknown statusDenmarkInjury of Gastrointestinal TractInfos
NCT01744509PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening ProgramInterventionalNot ApplicableUnknown statusItalyColon CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusAustriaMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusBelgiumMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusDenmarkMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusEstoniaMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusGermanyMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusGreeceMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusItalyMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusNetherlandsMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusNorwayMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusRomaniaMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusRussian FederationMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusSpainMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusSwedenMetastatic Colorectal CancerInfos
NCT01754272A Non-Interventional Follow-Up to the VELOUR Study - Translational ResearchObservationalN/AUnknown statusUnited KingdomMetastatic Colorectal CancerInfos
NCT01761097Endocuff Adenoma Detection Rate Pilot StudyInterventionalNot ApplicableUnknown statusUnited KingdomColorectal CancerInfos
NCT01762813Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal CancerObservationalN/ARecruitment openNorwayColorectal CancerInfos
NCT01779583Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study")ObservationalN/AUnknown statusSpainGastric CancerInfos
NCT01786122Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer PatientsInterventionalNot ApplicableUnknown statusSpainDigestive System NeoplasmsInfos
NCT01786200Physiological Effects of Altering Cancer-related InflammationInterventionalNot ApplicableUnknown statusUnited KingdomColon CancerInfos
NCT01787539The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric CancerInterventionalPhase 2/Phase 3Unknown statusPolandGastric CancerInfos
NCT01792934Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer MetastasesInterventionalNot ApplicableRecruitment openNetherlandsMulti-organ Metastatic Colorectal CancerInfos
NCT01792934Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer MetastasesInterventionalNot ApplicableRecruitment openUnited KingdomMulti-organ Metastatic Colorectal CancerInfos
NCT01795768Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified TumoursInterventionalPhase 2Unknown statusUnited KingdomGastric CancerInfos
NCT01795768Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified TumoursInterventionalPhase 2Unknown statusUnited KingdomOesophageal CancerInfos
NCT01801904A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal CancerInterventionalPhase 2Active but recruitment closedItalyMetastatic Colorectal CancerInfos
NCT01802645Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver MetastasesInterventionalPhase 2Unknown statusGermanyColorectal CancerInfos
NCT01814150The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With DocetaxelObservationalN/AUnknown statusIsraelMetastatic Gastric CancerInfos
NCT01827553Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction ChemotherapyInterventionalPhase 3Active but recruitment closedGermanyPancreatic CancerInfos
NCT01843829A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal CancerInterventionalPhase 2Unknown statusUnited KingdomOesophageal CancerInfos
NCT01845337Study to Compare Cardiovascular Side Effects of Teysuno Versus CapecitabineInterventionalPhase 2Unknown statusUnited KingdomGastrointestinal CancerInfos
NCT01845337Study to Compare Cardiovascular Side Effects of Teysuno Versus CapecitabineInterventionalPhase 2Unknown statusUnited KingdomPancreatic CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedAustriaLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedAustriaLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedAustriaLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedBelgiumLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedBelgiumLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedBelgiumLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedCzechiaLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedCzechiaLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedCzechiaLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedFinlandLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedFinlandLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedFinlandLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedFranceLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedFranceLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedFranceLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedGermanyLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedGermanyLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedGermanyLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedHungaryLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedHungaryLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedHungaryLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedIrelandLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedIrelandLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedIrelandLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedItalyLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedItalyLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedItalyLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedLuxembourgLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedLuxembourgLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedLuxembourgLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedNetherlandsLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedNetherlandsLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedNetherlandsLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedNorwayLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedNorwayLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedNorwayLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedSwedenLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedSwedenLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedSwedenLow-grade Serous Peritoneal CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedUnited KingdomLow-grade Serous Fallopian Tube CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedUnited KingdomLow-grade Serous Ovarian CancerInfos
NCT01849874A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerInterventionalPhase 3Active but recruitment closedUnited KingdomLow-grade Serous Peritoneal CancerInfos
NCT01853059Functional Outcomes Following Anal Cancer TreatmentObservationalN/AUnknown statusUnited KingdomAnal CancerInfos
NCT01879878Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]InterventionalNot ApplicableUnknown statusGermanyPancreatic Ductal AdenocarcinomaInfos
NCT01885702Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSIInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsColorectal CancerInfos
NCT01891539Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular CarcinomaObservationalN/AUnknown statusItalyLiver Cell Carcinoma Non-resectableInfos
NCT01892527Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High SubjectsInterventionalPhase 2Unknown statusItalyColorectal Cancer MetastaticInfos
NCT01895257Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal CancerInterventionalPhase 3Unknown statusBelgiumColorectal CancerInfos
NCT01898104Preoperative Valproic Acid and Radiation Therapy for Rectal CancerInterventionalPhase 1/Phase 2Recruitment openItalyColorectal CancerInfos
NCT01898741Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic CancerInterventionalPhase 2Unknown statusNetherlandsPancreatic CancerInfos
NCT01910610Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerInterventionalPhase 3Recruitment openFranceColorectal Cancer MetastaticInfos
NCT01910610Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerInterventionalPhase 3Recruitment openIrelandColorectal Cancer MetastaticInfos
NCT01910610Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerInterventionalPhase 3Recruitment openIsraelColorectal Cancer MetastaticInfos
NCT01918527Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon CancerInterventionalPhase 3Active but recruitment closedDenmarkColon CancerInfos
NCT01918527Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon CancerInterventionalPhase 3Active but recruitment closedNorwayColon CancerInfos
NCT01918527Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon CancerInterventionalPhase 3Active but recruitment closedSwedenColon CancerInfos
NCT01919151Micrometastasis in Gastrointestinal CancerObservationalN/AUnknown statusNorwayColorectal CancerInfos
NCT01919151Micrometastasis in Gastrointestinal CancerObservationalN/AUnknown statusNorwayPancreatic AdenocarcinomaInfos
NCT01927328Iron Replacement in Oesophagogastric NeoplasiaInterventionalPhase 4Unknown statusUnited KingdomEsophageal CancerInfos
NCT01927328Iron Replacement in Oesophagogastric NeoplasiaInterventionalPhase 4Unknown statusUnited KingdomGastric CancerInfos
NCT01937429Effectiveness of Instillation of Blue Water (Indigo Carmin®) for ColonoscopyInterventionalPhase 3Unknown statusFranceAdenoma Detection to Prevent Colorectal CancerInfos
NCT01937780Anal Cancer Radiotherapy StudyObservationalN/AActive but recruitment closedNorwayAnal CancerInfos
NCT01939665PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic CarcinomaInterventionalPhase 1/Phase 2Unknown statusNetherlandsPancreatic CancerInfos
NCT01943786RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-CetuximabObservationalN/AUnknown statusSpainColorectal Cancer MetastaticInfos
NCT01945723Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy VolunteersObservationalN/AUnknown statusIsraelHealthyInfos
NCT01958697Age and Gender Corrected Body Mass IndexObservationalN/AUnknown statusBelgiumEsophageal CancerInfos
NCT01959906Circumferential Section Pane Less Than 1 mm in Esophagectomy for Esophageal Cancer.ObservationalN/AUnknown statusBelgiumEsophageal CancerInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedAustriaPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedBelgiumPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedCzechiaPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedDenmarkPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFinlandPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFranceNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFrancePancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedFrancePancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedGermanyPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedHungaryPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedIrelandPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedItalyPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedNetherlandsPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedPortugalPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedSpainPancreatic NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomAntimetabolites, AntineoplasticInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomDigestive System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomDigestive System NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomEndocrine Gland NeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomEndocrine System DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomGemcitabineInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomNeoplasmsInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomNeoplasms by SiteInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomPancreatic DiseasesInfos
NCT01964430Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)InterventionalPhase 3Active but recruitment closedUnited KingdomPancreatic NeoplasmsInfos
NCT01964534Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic CancerInterventionalPhase 2Unknown statusFranceMetastatic Pancreatic CancerInfos
NCT01966081AGARIC Case Control StudyInterventionalNot ApplicableUnknown statusFranceFirst Recently-diagnosed Colorectal CancerInfos
NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterventionalPhase 3Active but recruitment closedBelgiumPeritoneal CancerInfos
NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterventionalPhase 3Active but recruitment closedFrancePeritoneal CancerInfos
NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterventionalPhase 3Active but recruitment closedGermanyPeritoneal CancerInfos
NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterventionalPhase 3Active but recruitment closedIsraelPeritoneal CancerInfos
NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterventionalPhase 3Active but recruitment closedItalyPeritoneal CancerInfos
NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterventionalPhase 3Active but recruitment closedSpainPeritoneal CancerInfos
NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerInterventionalPhase 3Active but recruitment closedUnited KingdomPeritoneal CancerInfos
NCT01983098Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer TreatmentObservationalN/AUnknown statusFranceTo Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan.Infos
NCT01991080The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant ChemotherapyInterventionalNot ApplicableUnknown statusIsraelColon CancerInfos
NCT01991873Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal CancerInterventionalPhase 2Active but recruitment closedGermanyMetastatic Colorectal CancerInfos
NCT01995942Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) TrialObservationalN/AUnknown statusUnited KingdomDigestive System NeoplasmsInfos
NCT02002195Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric CancerObservationalN/AUnknown statusItalyMetastatic Gastric CancerInfos
NCT02002299Does Surface Tell us About the Invasive Front in Colorectal CancerObservationalN/AUnknown statusDenmarkColorectal CancerInfos
NCT02005965Low Rectal Cancer Study (MERCURY II)ObservationalN/AUnknown statusGermanyDigestive System NeoplasmsInfos
NCT02005965Low Rectal Cancer Study (MERCURY II)ObservationalN/AUnknown statusSerbiaDigestive System NeoplasmsInfos
NCT02005965Low Rectal Cancer Study (MERCURY II)ObservationalN/AUnknown statusUnited KingdomDigestive System NeoplasmsInfos
NCT02007148MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric CancerInterventionalPhase 2Unknown statusItalyGastric AdenocarcinomaInfos
NCT02007148MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric CancerInterventionalPhase 2Unknown statusItalyGastroesophageal Junction AdenocarcinomaInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyAnal CancerInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyColon CancerInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyEsophageal CancerInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyFamilial Adenomatous PolyposisInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyGastric CancerInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyLiver CancerInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyLynch SyndromeInfos
NCT02012699Integrated Cancer Repository for Cancer ResearchObservationalN/ARecruitment openItalyPancreatic CancerInfos
NCT02017366Design of the EFECTS TrialInterventionalNot ApplicableUnknown statusBelgiumEsophageal CancerInfos
NCT02024009Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2InterventionalPhase 1/Phase 2Unknown statusUnited KingdomPancreatic Neoplasms (Locally Advanced Non-metastatic)Infos
NCT02039336Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCInterventionalPhase 1/Phase 2Unknown statusNetherlandsColorectal CancerInfos
NCT02045680RADOX' Reduced Abdominal Distension and Oxygen DeliveryObservationalN/AUnknown statusUnited KingdomColorectal CancerInfos
NCT02047513Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic CancerInterventionalPhase 2Active but recruitment closedGermanyDuctal Adenocarcinoma of the PancreasInfos
NCT02047513Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic CancerInterventionalPhase 2Active but recruitment closedGermanyResectable Pancreatic CancerInfos
NCT02047994Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityInterventionalPhase 4Recruitment openLatviaAtrophic GastritisInfos
NCT02047994Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityInterventionalPhase 4Recruitment openLatviaGastric CancerInfos
NCT02047994Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityInterventionalPhase 4Recruitment openLatviaHelicobacter Pylori InfectionsInfos
NCT02051283Pretreatment MRI Predicting Outcome After Radio-frequency Ablation of HCCObservationalN/AUnknown statusBelgiumHepatocellular CarcinomaInfos
NCT02051868International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly PaclitaxelInterventionalPhase 2Unknown statusUnited KingdomSquamous Cell Carcinoma of the AnusInfos
NCT02052778A Study of TAS-120 in Patients With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFranceGastric CancerInfos
NCT02052778A Study of TAS-120 in Patients With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyGastric CancerInfos
NCT02052778A Study of TAS-120 in Patients With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyGastric CancerInfos
NCT02052778A Study of TAS-120 in Patients With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsGastric CancerInfos
NCT02052778A Study of TAS-120 in Patients With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedPortugalGastric CancerInfos
NCT02052778A Study of TAS-120 in Patients With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainGastric CancerInfos
NCT02052778A Study of TAS-120 in Patients With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedUnited KingdomGastric CancerInfos
NCT02053805Prostate Cancer Screening Among Men With High Risk Genetic PredispositionInterventionalNot ApplicableUnknown statusIsraelLynch SyndromeInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedBelgiumMicrosatellite Stable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedBelgiumMicrosatellite Unstable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedBelgiumMismatch Repair Deficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedBelgiumMismatch Repair Proficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedFranceMicrosatellite Stable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedFranceMicrosatellite Unstable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedFranceMismatch Repair Deficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedFranceMismatch Repair Proficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedIrelandMicrosatellite Stable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedIrelandMicrosatellite Unstable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedIrelandMismatch Repair Deficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedIrelandMismatch Repair Proficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedItalyMicrosatellite Stable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedItalyMicrosatellite Unstable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedItalyMismatch Repair Deficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedItalyMismatch Repair Proficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedSpainMicrosatellite Stable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedSpainMicrosatellite Unstable Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedSpainMismatch Repair Deficient Colorectal CancerInfos
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadInterventionalPhase 2Active but recruitment closedSpainMismatch Repair Proficient Colorectal CancerInfos
NCT02066259OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study ProtocolObservationalN/AUnknown statusIsraelColon CancerInfos
NCT02070146Prospective Data Collection Initiative on Colorectal CancerObservationalN/ARecruitment openNetherlandsColorectal CancerInfos
NCT02075086Angiogenic Switch in Patients With Colorectal CancerInterventionalPhase 2Unknown statusSpainColorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusAustriaMetastatic Colorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusBelgiumMetastatic Colorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusEstoniaMetastatic Colorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusFranceMetastatic Colorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusGermanyMetastatic Colorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusItalyMetastatic Colorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusSpainMetastatic Colorectal CancerInfos
NCT02077868Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction TreatmentInterventionalPhase 3Unknown statusUnited KingdomMetastatic Colorectal CancerInfos
NCT02078245Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.ObservationalN/ARecruitment openSwedenHereditary Pancreatic CancerInfos
NCT02078245Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.ObservationalN/ARecruitment openSwedenHereditary PancreatitisInfos
NCT02079363DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic CancerObservationalN/AUnknown statusDenmarkPancreatic DiseasesInfos
NCT02079363DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic CancerObservationalN/AUnknown statusDenmarkPancreatic NeoplasmsInfos
NCT02079363DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic CancerObservationalN/AUnknown statusDenmarkPancreatitisInfos
NCT02089269Tumor Registry Pancreatic CancerObservationalN/AActive but recruitment closedGermanyPancreas CancerInfos
NCT02112357Feasibility of a Molecular Characterisation Approach to TreatmentObservationalN/AUnknown statusUnited KingdomAdvanced Gastrointestinal CancersInfos
NCT02125409Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of ActionInterventionalPhase 3Unknown statusSpainColorectal CancerInfos
NCT02138370Comprehensive Immune-landscape in Localized Colorectal CancerObservationalN/AUnknown statusSwitzerlandColorectal CancerInfos
NCT02138370Comprehensive Immune-landscape in Localized Colorectal CancerObservationalN/AUnknown statusSwitzerlandImmune LandscapeInfos
NCT02143219Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic CancerInterventionalPhase 2Active but recruitment closedFrancePancreatic Metastatic CancerInfos
NCT02143219Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic CancerInterventionalPhase 2Active but recruitment closedFranceToxicityInfos
NCT02145013Portal Hypertension and Liver Resection in Patients With Hepatocellular CarcinomaObservationalN/AUnknown statusFrancePrimary Liver CancersInfos
NCT02162563Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only MetastasesInterventionalPhase 3Recruitment openBelgiumColorectal CancerInfos
NCT02162563Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only MetastasesInterventionalPhase 3Recruitment openBelgiumLiver MetastasesInfos
NCT02162563Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only MetastasesInterventionalPhase 3Recruitment openNetherlandsColorectal CancerInfos
NCT02162563Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only MetastasesInterventionalPhase 3Recruitment openNetherlandsLiver MetastasesInfos
NCT02164149Length of Tumour Feeding Artery After Colon Cancer SurgeryObservationalN/AUnknown statusDenmarkColon CancerInfos
NCT02175914Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous PolyposisInterventionalPhase 4Unknown statusIsraelFAP-Familial Adenomatous PolyposisInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedBelgiumGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedBelgiumMetastatic Adenocarcinoma of the PancreasInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedFranceGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedFranceMetastatic Adenocarcinoma of the PancreasInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedGermanyGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedGermanyMetastatic Adenocarcinoma of the PancreasInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedIsraelGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedIsraelMetastatic Adenocarcinoma of the PancreasInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedItalyGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedItalyMetastatic Adenocarcinoma of the PancreasInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedNetherlandsGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedNetherlandsMetastatic Adenocarcinoma of the PancreasInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedSpainGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedSpainMetastatic Adenocarcinoma of the PancreasInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedUnited KingdomGermline BRCA1/2 Mutations andInfos
NCT02184195Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyInterventionalPhase 3Active but recruitment closedUnited KingdomMetastatic Adenocarcinoma of the PancreasInfos
NCT02184663Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic CancerInterventionalNot ApplicableUnknown statusFranceMetastatic Pancreatic CancerInfos
NCT02184663Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic CancerInterventionalNot ApplicableUnknown statusFranceUnresectable Locally Advanced CancerInfos
NCT02188927Effect of an Advanced Notification Letter on Screening Colonoscopy ParticipationInterventionalNot ApplicableUnknown statusPolandColorectal CancerInfos
NCT02197351Narrow Band Imaging for Gastric NeoplasiaInterventionalNot ApplicableRecruitment openPortugalGastric CancerInfos
NCT02208804Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 RadioembolizationInterventionalPhase 2/Phase 3Unknown statusNetherlandsDigestive System NeoplasmsInfos
NCT02209415EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic CancerInterventionalNot ApplicableUnknown statusDenmarkEsophageal CancerInfos
NCT02209415EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic CancerInterventionalNot ApplicableUnknown statusDenmarkPancreatic CancerInfos
NCT02209415EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic CancerInterventionalNot ApplicableUnknown statusDenmarkStomach CancerInfos
NCT02215577ALPPS Versus PVE/PLInterventionalNot ApplicableUnknown statusDenmarkColorectal CancerInfos
NCT02215577ALPPS Versus PVE/PLInterventionalNot ApplicableUnknown statusNorwayColorectal CancerInfos
NCT02215577ALPPS Versus PVE/PLInterventionalNot ApplicableUnknown statusSwedenColorectal CancerInfos
NCT02215889Partial Liver Segment 2/3 Transplantation StudyInterventionalPhase 1/Phase 2Recruitment openNorwayColorectal CancerInfos
NCT02230553Lapatinib Plus Trametinib in KRAS Mutant NSCLCInterventionalPhase 1/Phase 2Unknown statusNetherlandsColorectal CancerInfos
NCT02231385Acetic Acid Colonoscopy Enhancement StudyInterventionalNot ApplicableUnknown statusItalyColorectal CancerInfos
NCT02246322A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions.InterventionalNot ApplicableUnknown statusItalyPancreatic CancerInfos
NCT02246634Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)InterventionalNot ApplicableUnknown statusUnited KingdomColorectal NeoplasmsInfos
NCT02246634Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)InterventionalNot ApplicableUnknown statusUnited KingdomHepatic NeoplasmsInfos
NCT02246634Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)InterventionalNot ApplicableUnknown statusUnited KingdomNeoplasm MetastasesInfos
NCT02246725Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.ObservationalN/AActive but recruitment closedSwedenTumor in Upper Gastrointestinal Canal or Patients With Colorectal CancerInfos
NCT02248519Laparoscopic Versus Open Gastrectomy for Gastric CancerInterventionalNot ApplicableActive but recruitment closedNetherlandsGastric CancerInfos
NCT02254941Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal CancerObservationalN/AActive but recruitment closedSpainMetastatic Colon CancerInfos
NCT02260128Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer SurgeryInterventionalNot ApplicableUnknown statusDenmarkPancreatic CancerInfos
NCT02260505Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)InterventionalPhase 3Recruitment openFranceGastrointestinal Stromal TumorsInfos
NCT02260505Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)InterventionalPhase 3Recruitment openFranceResected Gastrointestinal Stromal TumorsInfos
NCT02272790Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 2Active but recruitment closedNetherlandsOvarian, Fallopian Tube, Peritoneal Cancer, P53 MutationInfos
NCT02272790Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 2Active but recruitment closedUnited KingdomOvarian, Fallopian Tube, Peritoneal Cancer, P53 MutationInfos
NCT02274753Personalizing Colorectal Cancer Medicine (ImmuCol2)ObservationalN/AActive but recruitment closedFranceColon CancerInfos
NCT02296203Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).InterventionalPhase 2Unknown statusItalyMetastatic Colorectal CancerInfos
NCT02299596Physical Activity in Relation to Surgical ProceduresInterventionalNot ApplicableActive but recruitment closedSwedenColorectal CancerInfos
NCT02300922Pretargeted Radioimmunotherapy in Metastatic Colorectal CancerInterventionalPhase 1/Phase 2Unknown statusFranceMetastatic Colorectal CancerInfos
NCT02301286A Trial of Aspirin on Recurrence and Survival in Colon Cancer PatientsInterventionalPhase 3Recruitment openNetherlandsAdjuvant TherapyInfos
NCT02301286A Trial of Aspirin on Recurrence and Survival in Colon Cancer PatientsInterventionalPhase 3Recruitment openNetherlandsColon CancerInfos
NCT02304978Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in AdultsInterventionalEarly Phase 1Unknown statusFranceColorectal CancerInfos
NCT02307500Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard TherapyInterventionalPhase 2Active but recruitment closedItalyPancreas CancerInfos
NCT02325323Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal MetaplasiaObservationalN/AUnknown statusFranceStomach CancerInfos
NCT02325453Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological OutcomesObservationalN/AUnknown statusItalyGastric CancerInfos
NCT02327494Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal SurgeryObservationalN/AUnknown statusSpainColorectal CancerInfos
NCT02327819The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver CancerInterventionalNot ApplicableUnknown statusIsraelPrimary Liver CancerInfos
NCT02328677ColoCare Study - Colorectal Cancer CohortObservationalN/ARecruitment openGermanyColorectal CancerInfos
NCT02331927PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal CancerInterventionalPhase 2Unknown statusGermanyMetastatic Colorectal CancerInfos
NCT02339116Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRCInterventionalPhase 3Unknown statusItalyMetastatic Colorectal CancerInfos
NCT02355119Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic CancerInterventionalPhase 3Unknown statusItalyPancreatic CancerInfos
NCT02356406Celiac Plexus Radiosurgery for Pain ManagementInterventionalPhase 2Unknown statusIsraelDigestive System NeoplasmsInfos
NCT02363049Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon CancerInterventionalPhase 3Unknown statusFranceColon Cancer Liver MetastasisInfos
NCT02363049Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon CancerInterventionalPhase 3Unknown statusFranceMalignant Neoplasm of Large IntestineInfos
NCT02372500Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal SurgeryInterventionalNot ApplicableUnknown statusUnited KingdomColorectal CancerInfos
NCT02379039Multimodal Monitoring of Radiotherapy Response in Squamous Cell CancerObservationalN/ARecruitment openSwedenAnal CancerInfos
NCT02379039Multimodal Monitoring of Radiotherapy Response in Squamous Cell CancerObservationalN/ARecruitment openSwedenEsophageal CancerInfos
NCT02395224A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-NorwayObservationalN/AActive but recruitment closedNorwayNeoplasm MetastasisInfos
NCT02395224A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-NorwayObservationalN/AActive but recruitment closedNorwayNeoplasms, ColorectalInfos
NCT02403050Feasibility Study of Fiducial Markers in Oesophageal CancerObservationalN/AUnknown statusUnited KingdomEsophageal NeoplasmsInfos
NCT02415101Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal CancerInterventionalNot ApplicableActive but recruitment closedSwedenCancer of the EsophagusInfos
NCT02416609Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic CancerInterventionalNot ApplicableRecruitment openItalyPancreatic CancerInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusGermanyHepatocellular CarcinomaInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusGermanyPancreatic CancerInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusPolandHepatocellular CarcinomaInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusPolandPancreatic CancerInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusSpainHepatocellular CarcinomaInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusSpainPancreatic CancerInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusUnited KingdomHepatocellular CarcinomaInfos
NCT02423239A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced TumoursInterventionalPhase 1Unknown statusUnited KingdomPancreatic CancerInfos
NCT02424279Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic LadderInterventionalNot ApplicableUnknown statusPolandPainInfos
NCT02424279Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic LadderInterventionalNot ApplicableUnknown statusPolandPancreatic CancerInfos
NCT02425657Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical DepartmentsObservationalN/AUnknown statusDenmarkColorectal CancerInfos
NCT02436564In Vitro Models of Liver and Pancreatic CancerObservationalN/AUnknown statusUnited KingdomCholangiocarcinomaInfos
NCT02436564In Vitro Models of Liver and Pancreatic CancerObservationalN/AUnknown statusUnited KingdomHepatocellular CarcinomaInfos
NCT02436564In Vitro Models of Liver and Pancreatic CancerObservationalN/AUnknown statusUnited KingdomPancreatic NeoplasmInfos
NCT02443948Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)ObservationalN/AUnknown statusItalyGastrointestinal Stromal Tumor (GIST)Infos
NCT02454790Standard Follow-Up Program (SFP) for Patients With Esophageal CancerObservationalN/ARecruitment openNetherlandsEsophageal CancerInfos
NCT02457156Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomyInterventionalPhase 3Active but recruitment closedUnited KingdomPancreatic CancerInfos
NCT02458664BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal CancerObservationalN/AUnknown statusFranceCancer of ColonInfos
NCT02458664BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal CancerObservationalN/AUnknown statusFranceRectum CancerInfos
NCT02467582Adjuvant Aspirin Treatment for Colon Cancer PatientsInterventionalPhase 3Active but recruitment closedBelgiumColon CancerInfos
NCT02467582Adjuvant Aspirin Treatment for Colon Cancer PatientsInterventionalPhase 3Active but recruitment closedGermanyColon CancerInfos
NCT02467582Adjuvant Aspirin Treatment for Colon Cancer PatientsInterventionalPhase 3Active but recruitment closedHungaryColon CancerInfos
NCT02467582Adjuvant Aspirin Treatment for Colon Cancer PatientsInterventionalPhase 3Active but recruitment closedSwitzerlandColon CancerInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkOvarian CancerInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkOvarian NeoplasmInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedIsraelOvarian CancerInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedIsraelOvarian NeoplasmInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandOvarian CancerInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandOvarian NeoplasmInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainOvarian CancerInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainOvarian NeoplasmInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedUnited KingdomOvarian CancerInfos
NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedUnited KingdomOvarian NeoplasmInfos
NCT02476045Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)InterventionalPhase 2Unknown statusItalyMetastatic Colorectal CancerInfos
NCT02489058A Study of Long-Term Responders on OlaparibObservationalN/AActive but recruitment closedItalyPeritoneal CancerInfos
NCT02489058A Study of Long-Term Responders on OlaparibObservationalN/AActive but recruitment closedSpainPeritoneal CancerInfos
NCT02489058A Study of Long-Term Responders on OlaparibObservationalN/AActive but recruitment closedUnited KingdomPeritoneal CancerInfos
NCT02494973Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver MetastasesInterventionalPhase 2/Phase 3Recruitment openFranceColorectal CancerInfos
NCT02497820Finding the Best Dose of Aspirin to Prevent Lynch Syndrome CancersInterventionalPhase 3Not yet recruitingIsraelLynch Syndrome I (Site-specific Colonic Cancer)Infos
NCT02502656RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal CancerObservationalN/AUnknown statusFranceColorectal CancerInfos
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedFranceHepatocellular Carcinoma (HCC)Infos
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedGermanyHepatocellular Carcinoma (HCC)Infos
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedItalyHepatocellular Carcinoma (HCC)Infos
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedSpainHepatocellular Carcinoma (HCC)Infos
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedSwitzerlandHepatocellular Carcinoma (HCC)Infos
NCT02508467A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedUnited KingdomHepatocellular Carcinoma (HCC)Infos
NCT02509507Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611InterventionalPhase 1/Phase 2Active but recruitment closedAustriaHepatocellular CarcinomaInfos
NCT02509507Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611InterventionalPhase 1/Phase 2Active but recruitment closedBelgiumHepatocellular CarcinomaInfos
NCT02509507Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611InterventionalPhase 1/Phase 2Active but recruitment closedGermanyHepatocellular CarcinomaInfos
NCT02509507Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611InterventionalPhase 1/Phase 2Active but recruitment closedPolandHepatocellular CarcinomaInfos
NCT02509507Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611InterventionalPhase 1/Phase 2Active but recruitment closedSpainHepatocellular CarcinomaInfos
NCT02509507Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611InterventionalPhase 1/Phase 2Active but recruitment closedSwitzerlandHepatocellular CarcinomaInfos
NCT02511223Efficacy and Safety of PARPi to Treat Pancreatic CancerInterventionalPhase 2Unknown statusIsraelPancreatic CancerInfos
NCT02512263Assessment of Adherence and Efficiency of a Home-based Training Program on Muscular Strength, Endurance and Qol for Colon Cancer PatientsInterventionalNot ApplicableUnknown statusBelgiumColon CancerInfos
NCT02513849Tamoxifen in Patients With Oesophageal CancerInterventionalPhase 1Unknown statusUnited KingdomCancerInfos
NCT02513849Tamoxifen in Patients With Oesophageal CancerInterventionalPhase 1Unknown statusUnited KingdomGastrointestinal NeoplasmsInfos
NCT02519348A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaInterventionalPhase 2Active but recruitment closedItalyHepatocellular CarcinomaInfos
NCT02519348A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaInterventionalPhase 2Active but recruitment closedSpainHepatocellular CarcinomaInfos
NCT02519582Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After TherapyInterventionalPhase 2Unknown statusGermanyColorectal CancerInfos
NCT02522520Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant ChemotherapyInterventionalNot ApplicableUnknown statusDenmarkColorectal CancerInfos
NCT02526264Evaluation of Quality of Life and Period of Hospitalization by EducationInterventionalNot ApplicableRecruitment openGermanyColorectal CancerInfos
NCT02526836Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon CancerInterventionalPhase 2/Phase 3Unknown statusItalyColon CancerInfos
NCT02530593QoLiCOL - Quality of Life in Colon CancerObservationalN/AActive but recruitment closedSwedenColonic NeoplasmInfos
NCT02539537A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic CarcinomaInterventionalPhase 3Active but recruitment closedFrancePancreatic CancerInfos
NCT02545699Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard ColonoscopyInterventionalNot ApplicableUnknown statusIsraelColorectal CancerInfos
NCT02546973Quality of Life in Patients With Anal CancerObservationalN/AActive but recruitment closedSwedenAnal CancerInfos
NCT02551458Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to RadiochemotherapyInterventionalPhase 2/Phase 3Recruitment openFranceAdenocarcinoma of the Oesogastric Junction (Siewert Type I or II)Infos
NCT02551458Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to RadiochemotherapyInterventionalPhase 2/Phase 3Recruitment openFranceAdenocarcinoma of the Thoracic Oesophagus orInfos
NCT02551458Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to RadiochemotherapyInterventionalPhase 2/Phase 3Recruitment openFranceEpidermoid Carcinoma orInfos
NCT02551458Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to RadiochemotherapyInterventionalPhase 2/Phase 3Recruitment openFranceStage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0Infos
NCT02556281Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-IIIInterventionalNot ApplicableUnknown statusFranceColorectal NeoplasmsInfos
NCT02564146First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and GemcitabineInterventionalPhase 2Active but recruitment closedGermanyAdenocarcinoma of the PancreasInfos
NCT02564146First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and GemcitabineInterventionalPhase 2Active but recruitment closedGermanyMetastatic Pancreatic CancerInfos
NCT02567253Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian CancerInterventionalPhase 2Unknown statusBelgiumPrimary Peritoneal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openBelgiumColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openBelgiumPancreatic CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openFranceColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openFrancePancreatic CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openGermanyColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openGermanyPancreatic CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openItalyColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openItalyPancreatic CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openNetherlandsColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openNetherlandsPancreatic CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openPolandColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openPolandPancreatic CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openSpainColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openSpainPancreatic CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openUnited KingdomColorectal CancerInfos
NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)InterventionalPhase 2Recruitment openUnited KingdomPancreatic CancerInfos
NCT02571036A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesInterventionalPhase 1Active but recruitment closedAustriaGastrointestinal Stromal TumorsInfos
NCT02571036A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesInterventionalPhase 1Active but recruitment closedGermanyGastrointestinal Stromal TumorsInfos
NCT02571036A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesInterventionalPhase 1Active but recruitment closedItalyGastrointestinal Stromal TumorsInfos
NCT02571036A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesInterventionalPhase 1Active but recruitment closedNetherlandsGastrointestinal Stromal TumorsInfos
NCT02571036A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesInterventionalPhase 1Active but recruitment closedSpainGastrointestinal Stromal TumorsInfos
NCT02571036A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesInterventionalPhase 1Active but recruitment closedUnited KingdomGastrointestinal Stromal TumorsInfos
NCT02574013Randomized Controlled Trial for Retractor SPONGE Evaluation in Laparoscopic Colorectal SurgeryInterventionalNot ApplicableUnknown statusNetherlandsColorectal CancerInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openBelgiumSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openCzechiaSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openDenmarkSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openFranceSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openGermanySolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openGreeceSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openHungarySolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openIrelandSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openItalySolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openNorwaySolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openPolandSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openPortugalSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openRussian FederationSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openSlovakiaSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openSpainSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openSwedenSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openTurkeySolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openUkraineSolid Tumors Harboring NTRK FusionInfos
NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsInterventionalPhase 2Recruitment openUnited KingdomSolid Tumors Harboring NTRK FusionInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedAustriaHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedBelgiumHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedCzechiaHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedFranceHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedGermanyHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedIsraelHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedItalyHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedPolandHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedRussian FederationHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedSpainHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedSwedenHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedSwitzerlandHepatocellular CarcinomaInfos
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaInterventionalPhase 3Active but recruitment closedUnited KingdomHepatocellular CarcinomaInfos
NCT02577627Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOCObservationalN/AUnknown statusIsraelColon CancerInfos
NCT02578368Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionInterventionalPhase 3Recruitment openGermanyGastric CancerInfos
NCT02591667Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal CancerInterventionalPhase 2Unknown statusAustriaColorectal CancerInfos
NCT02591667Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal CancerInterventionalPhase 2Unknown statusAustriaPeritoneal MetastasisInfos
NCT02597075Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line ChemotherapyInterventionalNot ApplicableActive but recruitment closedAustriaMetastatic Colorectal CancerInfos
NCT02597075Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line ChemotherapyInterventionalNot ApplicableActive but recruitment closedSwitzerlandMetastatic Colorectal CancerInfos
NCT02597348Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by ChemotherapyInterventionalNot ApplicableActive but recruitment closedFranceColorectal CancerInfos
NCT02614534Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal CarcinomaInterventionalPhase 3Active but recruitment closedSpainColorectal CancerInfos
NCT02618850PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical TreatmentInterventionalNot ApplicableActive but recruitment closedItalyColorectal Cancer Stage IVInfos
NCT02619435Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal CancerInterventionalPhase 2Active but recruitment closedItalyAdvanced Colorectal CancerInfos
NCT02624271Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer RiskInterventionalNot ApplicableUnknown statusFranceGastric CancerInfos
NCT02624271Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer RiskInterventionalNot ApplicableUnknown statusFranceGastric Precancerous LesionsInfos
NCT02624726Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line TreatmentInterventionalPhase 2Unknown statusGreeceMetastatic Colorectal CancerInfos
NCT02626377Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-ComtéInterventionalNot ApplicableRecruitment openFranceColorectal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openDenmarkAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openFranceAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openGermanyAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openIsraelAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openItalyAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openNetherlandsAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openNorwayAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openRussian FederationAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openSpainAnal CancerInfos
NCT02628067Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)InterventionalPhase 2Recruitment openUnited KingdomAnal CancerInfos
NCT02633098A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal CancerInterventionalPhase 2Active but recruitment closedUnited KingdomBowel CancerInfos
NCT02633098A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal CancerInterventionalPhase 2Active but recruitment closedUnited KingdomColorectal CancerInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openCzechiaSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openDenmarkSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openFranceSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openGermanySolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openIrelandSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openIsraelSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openItalySolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openNetherlandsSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openPolandSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openRussian FederationSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openSpainSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openSwedenSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openSwitzerlandSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openTurkeySolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openUkraineSolid Tumors Harboring NTRK FusionInfos
NCT02637687A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenInterventionalPhase 1/Phase 2Recruitment openUnited KingdomSolid Tumors Harboring NTRK FusionInfos
NCT02638766Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GISTInterventionalPhase 2Recruitment openFranceGastrointestinal Stromal TumorsInfos
NCT02638766Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GISTInterventionalPhase 2Recruitment openItalyGastrointestinal Stromal TumorsInfos
NCT02638766Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GISTInterventionalPhase 2Recruitment openSpainGastrointestinal Stromal TumorsInfos
NCT02646462Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic CancerObservationalN/AUnknown statusDenmarkPancreatic CancerInfos
NCT02647099Adjuvant Low Dose Aspirin in Colorectal CancerInterventionalPhase 3Recruitment openDenmarkColorectal CancerInfos
NCT02647099Adjuvant Low Dose Aspirin in Colorectal CancerInterventionalPhase 3Recruitment openFinlandColorectal CancerInfos
NCT02647099Adjuvant Low Dose Aspirin in Colorectal CancerInterventionalPhase 3Recruitment openNorwayColorectal CancerInfos
NCT02647099Adjuvant Low Dose Aspirin in Colorectal CancerInterventionalPhase 3Recruitment openSwedenColorectal CancerInfos
NCT02649790Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsInterventionalPhase 1/Phase 2Recruitment openFranceMetastatic Colorectal Cancer (mCRC)Infos
NCT02649790Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsInterventionalPhase 1/Phase 2Recruitment openSpainMetastatic Colorectal Cancer (mCRC)Infos
NCT02665312Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving FluoropyrimidineObservationalN/AUnknown statusItalyColorectal CancerInfos
NCT02668913LCC-CARIS-01: Molecular Profiling in Gynaecological CancerInterventionalPhase 1/Phase 2Unknown statusUnited KingdomPeritoneal CancerInfos
NCT02672774Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal CancersInterventionalNot ApplicableUnknown statusRomaniaColorectal CancerInfos
NCT02672774Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal CancersInterventionalNot ApplicableUnknown statusRomaniaGastric CancerInfos
NCT02672774Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal CancersInterventionalNot ApplicableUnknown statusRomaniaGastrointestinal NeoplasmsInfos
NCT02674100American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) RegistryObservationalN/AActive but recruitment closedUnited KingdomPancreatic CancerInfos
NCT02674373Prognostic and Predictive Impact of Circulating Tumor DNA in Gastric Cancer TreatmentObservationalN/AUnknown statusFranceGastric CancerInfos
NCT02678182Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialInterventionalPhase 2Recruitment openUnited KingdomAdenocarcinoma of the Gastro-oesophageal JunctionInfos
NCT02678182Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialInterventionalPhase 2Recruitment openUnited KingdomAdenocarcinoma of the OesophagusInfos
NCT02678182Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialInterventionalPhase 2Recruitment openUnited KingdomAdenocarcinoma of the StomachInfos
NCT02687321The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal CancerObservationalN/AUnknown statusCzechiaOvarian NeoplasmsInfos
NCT02687321The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal CancerObservationalN/AUnknown statusHungaryOvarian NeoplasmsInfos
NCT02687321The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal CancerObservationalN/AUnknown statusPolandOvarian NeoplasmsInfos
NCT02687321The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal CancerObservationalN/AUnknown statusSlovakiaOvarian NeoplasmsInfos
NCT02687321The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal CancerObservationalN/AUnknown statusSpainOvarian NeoplasmsInfos
NCT02687321The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal CancerObservationalN/AUnknown statusUkraineOvarian NeoplasmsInfos
NCT02697084Individual Following in Anal Cancer With PET/CTObservationalN/ARecruitment openFranceAnal CancerInfos
NCT02701088Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of LifeInterventionalPhase 2Recruitment openFranceLocally Advanced Anal Canal CancerInfos
NCT02702414Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)InterventionalPhase 2Active but recruitment closedBelgiumHepatocellular CarcinomaInfos
NCT02702414Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)InterventionalPhase 2Active but recruitment closedFranceHepatocellular CarcinomaInfos
NCT02702414Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)InterventionalPhase 2Active but recruitment closedGermanyHepatocellular CarcinomaInfos
NCT02702414Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)InterventionalPhase 2Active but recruitment closedItalyHepatocellular CarcinomaInfos
NCT02702414Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)InterventionalPhase 2Active but recruitment closedSwedenHepatocellular CarcinomaInfos
NCT02702414Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)InterventionalPhase 2Active but recruitment closedUnited KingdomHepatocellular CarcinomaInfos
NCT02704832Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)InterventionalPhase 3Unknown statusFranceColorectal CancerInfos
NCT02705300Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal CancerInterventionalPhase 2Active but recruitment closedDenmarkColorectal CancerInfos
NCT02707159Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer PatientsInterventionalPhase 2Unknown statusNorwayMetastatic Pancreatic CancerInfos
NCT02707796Correlation Between Partial Oxygen Pressure and Oxygen Reserve IndexInterventionalNot ApplicableUnknown statusTurkeyCOLON CANCERInfos
NCT02715882Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal CancerInterventionalPhase 2Unknown statusRussian FederationColorectal CancerInfos
NCT02716012First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver CancerInterventionalPhase 1Active but recruitment closedUnited KingdomHepatocellular CarcinomaInfos
NCT02716012First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver CancerInterventionalPhase 1Active but recruitment closedUnited KingdomLiver CancerInfos
NCT02726243Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel DiseaseObservationalN/AUnknown statusFranceColorectal CancerInfos
NCT02726243Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel DiseaseObservationalN/AUnknown statusFranceInflammatory Bowel DiseaseInfos
NCT02732301Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for BiomarkersObservationalN/AActive but recruitment closedSwedenGastrointestinal TractInfos
NCT02738359Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer ScreeningObservationalN/ARecruitment openFranceColon CancerInfos
NCT02738359Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer ScreeningObservationalN/ARecruitment openFranceRectum CancerInfos
NCT02741167Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal ChemotherapyObservationalN/AUnknown statusSwitzerlandPeritoneal CancerInfos
NCT02741856Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose EscalationInterventionalPhase 2/Phase 3Recruitment openUnited KingdomOesophageal CancerInfos
NCT02745600Clinical Intervention Modelling, Planning and Proof for Ablation Cancer TreatmentInterventionalNot ApplicableUnknown statusAustriaHepatocellular CarcinomaInfos
NCT02745600Clinical Intervention Modelling, Planning and Proof for Ablation Cancer TreatmentInterventionalNot ApplicableUnknown statusFinlandHepatocellular CarcinomaInfos
NCT02745600Clinical Intervention Modelling, Planning and Proof for Ablation Cancer TreatmentInterventionalNot ApplicableUnknown statusGermanyHepatocellular CarcinomaInfos
NCT02745600Clinical Intervention Modelling, Planning and Proof for Ablation Cancer TreatmentInterventionalNot ApplicableUnknown statusNetherlandsHepatocellular CarcinomaInfos
NCT02748551A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric CancerInterventionalPhase 3Unknown statusRussian FederationGastric CancerInfos
NCT02748551A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric CancerInterventionalPhase 3Unknown statusUkraineGastric CancerInfos
NCT02751086Robotic, Laparoscopic and Open Gastrectomy Compared on Short and Long Term OutcomesObservationalN/ARecruitment openItalyGastric CancerInfos
NCT02756455Procalcitonin Reveals Early Dehiscence in Gastric Surgery: the PREDIGS StudyObservationalN/AUnknown statusItalyGastric CancerInfos
NCT02756468Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS StudyObservationalN/AUnknown statusItalyPancreatic CancerInfos
NCT02758951Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal MetastasesInterventionalPhase 2/Phase 3Recruitment openBelgiumColorectal CancerInfos
NCT02758951Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal MetastasesInterventionalPhase 2/Phase 3Recruitment openBelgiumPeritoneal CancerInfos
NCT02758951Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal MetastasesInterventionalPhase 2/Phase 3Recruitment openNetherlandsColorectal CancerInfos
NCT02758951Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal MetastasesInterventionalPhase 2/Phase 3Recruitment openNetherlandsPeritoneal CancerInfos
NCT02758977Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)InterventionalNot ApplicableUnknown statusSwitzerlandColon Cancer Liver MetastasesInfos
NCT02759601Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)InterventionalPhase 1/Phase 2Unknown statusUnited KingdomHepatocellular CarcinomaInfos
NCT02767557Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer PatientsInterventionalPhase 2Active but recruitment closedDenmarkUnresectable Pancreatic CarcinomaInfos
NCT02767557Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer PatientsInterventionalPhase 2Active but recruitment closedNorwayUnresectable Pancreatic CarcinomaInfos
NCT02780921Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control TrialInterventionalPhase 3Unknown statusFranceGastric CancerInfos
NCT02780921Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control TrialInterventionalPhase 3Unknown statusFranceOesophageal CancerInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedAustriaColon Cancer Liver MetastasisInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedAustriaColorectal CancerInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedBelgiumColon Cancer Liver MetastasisInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedBelgiumColorectal CancerInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedFranceColon Cancer Liver MetastasisInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedFranceColorectal CancerInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedPolandColon Cancer Liver MetastasisInfos
NCT02781935Diffusion-Weighted MRI for Liver MetastasisObservationalN/AActive but recruitment closedPolandColorectal CancerInfos
NCT02785263Shared Decision Making With Anal Cancer Patients on Radiation DoseInterventionalNot ApplicableActive but recruitment closedDenmarkAnal CancerInfos
NCT02786329Anesthesia and Postoperative Outcome in Colorectal Cancer PatientsInterventionalEarly Phase 1Recruitment openRomaniaColorectal CancerInfos
NCT02786342Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With SorafenibObservationalN/AActive but recruitment closedItalyHepatocellular CarcinomaInfos
NCT02788669LRP1 and Colon CancerObservationalN/AUnknown statusFranceAdenocarcinomaInfos
NCT02788669LRP1 and Colon CancerObservationalN/AUnknown statusFranceColon CancerInfos
NCT02789709Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive BiomarkersObservationalN/AUnknown statusSpainColon CancerInfos
NCT02791334A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsInterventionalPhase 1Active but recruitment closedBelgiumPancreatic CancerInfos
NCT02791334A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsInterventionalPhase 1Active but recruitment closedFrancePancreatic CancerInfos
NCT02791334A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsInterventionalPhase 1Active but recruitment closedIsraelPancreatic CancerInfos
NCT02791334A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsInterventionalPhase 1Active but recruitment closedNetherlandsPancreatic CancerInfos
NCT02791334A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsInterventionalPhase 1Active but recruitment closedSpainPancreatic CancerInfos
NCT02792023Usefulness of Fecal Immunochemical Test in Iron Deficiency Anemia (IDAFIT)InterventionalNot ApplicableUnknown statusSpainColorectal CancerInfos
NCT02795988A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric CancerInterventionalPhase 1/Phase 2Active but recruitment closedGeorgiaAdenocarcinomaInfos
NCT02795988A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric CancerInterventionalPhase 1/Phase 2Active but recruitment closedGeorgiaGastrointestinal NeoplasmsInfos
NCT02795988A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric CancerInterventionalPhase 1/Phase 2Active but recruitment closedSerbiaAdenocarcinomaInfos
NCT02795988A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric CancerInterventionalPhase 1/Phase 2Active but recruitment closedSerbiaGastrointestinal NeoplasmsInfos
NCT02795988A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric CancerInterventionalPhase 1/Phase 2Active but recruitment closedUkraineAdenocarcinomaInfos
NCT02795988A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric CancerInterventionalPhase 1/Phase 2Active but recruitment closedUkraineGastrointestinal NeoplasmsInfos
NCT02798003Food Reward in Cachexia Induced by Acute or Chronic DiseaseObservationalN/AUnknown statusNetherlandsPancreatic CancerInfos
NCT02799212Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular CarcinomaInterventionalPhase 3Recruitment openFranceHepatocellular CarcinomaInfos
NCT02804802Impact of DietarY and LIfestyle Risk Factors on Colorectal Cancer ScreeningObservationalN/AUnknown statusFranceColorectal CancerInfos
NCT02804815Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid TumoursInterventionalPhase 3Recruitment openIrelandColorectal CancerInfos
NCT02804815Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid TumoursInterventionalPhase 3Recruitment openIrelandGastro-oesophageal CancerInfos
NCT02804815Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid TumoursInterventionalPhase 3Recruitment openUnited KingdomColorectal CancerInfos
NCT02804815Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid TumoursInterventionalPhase 3Recruitment openUnited KingdomGastro-oesophageal CancerInfos
NCT02806687Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic CancerInterventionalPhase 2Active but recruitment closedFrancePancreatic AdenocarcinomaInfos
NCT02811666Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive CancersInterventionalNot ApplicableUnknown statusFranceLiver CancerInfos
NCT02811666Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive CancersInterventionalNot ApplicableUnknown statusFrancePancreatic CancerInfos
NCT02813824Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch SyndromeInterventionalPhase 3Recruitment openFranceLynch SyndromeInfos
NCT02813928Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative TreatmentInterventionalNot ApplicableUnknown statusFranceColorectal CancerInfos
NCT02818907Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially ResectableInterventionalNot ApplicableRecruitment openFrancePancreatic CancerInfos
NCT02820389CT Colonography as the Initial Diagnostic Imaging Tool for Patients With Suspected Colorectal CancerObservationalN/AUnknown statusUnited KingdomColorectal CancerInfos
NCT02821793Expectations and Priorities of Elderly Patients for a First Medical Treatment for CancerObservationalN/AUnknown statusFranceColorectal CancerInfos
NCT02824185Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular CarcinomaInterventionalNot ApplicableRecruitment openFrancePatients Eligible to a Curative Treatment for Primary HCCInfos
NCT02824484A Guided Written Disclosure Intervention to Promote Post-traumatic Growth in Cancer Patients GUIDED WRITTEN DISCLOSUREInterventionalNot ApplicableUnknown statusItalyColorectal CancerInfos
NCT02826486Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)InterventionalPhase 2Active but recruitment closedIsraelMetastatic Pancreatic AdenocarcinomaInfos
NCT02826486Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)InterventionalPhase 2Active but recruitment closedSpainMetastatic Pancreatic AdenocarcinomaInfos
NCT028416573D Laparoscopy Versus 2D LaparoscopyObservationalN/AUnknown statusItalyColorectal CancerInfos
NCT02842294Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal CancerObservationalN/AUnknown statusFranceMetastatic Colorectal CancerInfos
NCT02842294Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal CancerObservationalN/AUnknown statusFranceQuality of LifeInfos
NCT02844608Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of BesanconInterventionalNot ApplicableUnknown statusFranceColorectal CancerInfos
NCT02847468Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With SorafenibInterventionalNot ApplicableUnknown statusFranceCarcinoma, HepatocellularInfos
NCT02848807Chemotherapy-related Toxicity, Nutritional Status and Quality of LifeInterventionalNot ApplicableUnknown statusPolandMetastatic Colorectal CancerInfos
NCT02853474Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line ChemotherapyInterventionalPhase 3Active but recruitment closedFranceBile Duct CancerInfos
NCT02853474Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line ChemotherapyInterventionalPhase 3Active but recruitment closedFranceEsophageal CancerInfos
NCT02853474Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line ChemotherapyInterventionalPhase 3Active but recruitment closedFranceGastric CancerInfos
NCT02853474Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line ChemotherapyInterventionalPhase 3Active but recruitment closedFranceGastroesophageal CancerInfos
NCT02853474Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line ChemotherapyInterventionalPhase 3Active but recruitment closedFrancePancreas CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedCzechiaEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedCzechiaFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedCzechiaOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedCzechiaPeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedHungaryEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedHungaryFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedHungaryOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedHungaryPeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedIsraelEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedIsraelFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedIsraelOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedIsraelPeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedItalyEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedItalyFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedItalyOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedItalyPeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedPolandEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedPolandFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedPolandOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedPolandPeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedRussian FederationEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedRussian FederationFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedRussian FederationOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedRussian FederationPeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedSpainEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedSpainFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedSpainOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedSpainPeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUkraineEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUkraineFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUkraineOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUkrainePeritoneal CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUnited KingdomEpithelial Ovarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUnited KingdomFallopian Tube CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUnited KingdomOvarian CancerInfos
NCT02855944ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsInterventionalPhase 3Active but recruitment closedUnited KingdomPeritoneal CancerInfos
NCT02857270A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerInterventionalPhase 1Active but recruitment closedFranceColorectal CancerInfos
NCT02857270A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerInterventionalPhase 1Active but recruitment closedGermanyColorectal CancerInfos
NCT02858141Onco-geriatric Database of Patients With Pancreatic CancerObservationalN/AUnknown statusFrancePancreatic NeoplasmsInfos
NCT02859753Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency AblationInterventionalNot ApplicableUnknown statusFranceHepatocellular CarcinomaInfos
NCT02861209Collaborative Network to Take Responsibility for Oral Anticancer TherapyInterventionalNot ApplicableRecruitment openBelgiumColorectal CancerInfos
NCT02861430Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular BiologyObservationalN/AUnknown statusFranceColon CancerInfos
NCT02861430Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular BiologyObservationalN/AUnknown statusFranceLymph NodeInfos
NCT02861430Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular BiologyObservationalN/AUnknown statusFranceSentinel NodeInfos
NCT02866383Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsInterventionalPhase 2Active but recruitment closedDenmarkMetastatic Biliary Tract CancerInfos
NCT02866383Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsInterventionalPhase 2Active but recruitment closedDenmarkMetastatic Pancreatic CancerInfos
NCT02869503Institut Paoli Calmettes Colorectal Cancer DatabaseObservationalN/ARecruitment openFranceColorectal NeoplasmsInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedCzechiaGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedFranceGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedGermanyGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedGreeceGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedHungaryGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedIsraelGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedItalyGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedPolandGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedPortugalGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedRomaniaGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedRussian FederationGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedSpainGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedTurkeyGastric CancerInfos
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerInterventionalPhase 3Active but recruitment closedUnited KingdomGastric CancerInfos
NCT02872779Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal CancerInterventionalNot ApplicableUnknown statusFranceCirculating MarkersInfos
NCT02872779Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal CancerInterventionalNot ApplicableUnknown statusFranceMetastatic Colorectal CancerInfos
NCT02873845Role of the Spouse/Partner of Persons Treated With Chemotherapy for Colon CancerObservationalN/AUnknown statusFranceColon CancerInfos
NCT02876133Narrow Band Imaging Versus White Light for Colonoscopy Serrate Lesions DetectionInterventionalNot ApplicableUnknown statusPortugalColon CancerInfos
NCT02884453Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric CarcinomaInterventionalPhase 2Unknown statusUnited KingdomGastrooesophageal CancerInfos
NCT02885142Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?InterventionalNot ApplicableUnknown statusFranceAnal CancerInfos
NCT02885753Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the LiverInterventionalPhase 3Recruitment openFranceColorectal NeoplasmsInfos
NCT02885753Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the LiverInterventionalPhase 3Recruitment openSwitzerlandColorectal NeoplasmsInfos
NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyColorectal Cancer (CRC)Infos
NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyGastric CancerInfos
NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsColorectal Cancer (CRC)Infos
NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsGastric CancerInfos
NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainColorectal Cancer (CRC)Infos
NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainGastric CancerInfos
NCT02904031Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly PatientsInterventionalPhase 2Unknown statusItalyElderly Metastatic Colorectal Cancer PatientsInfos
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairInterventionalPhase 3Recruitment openGermanyColon AdenocarcinomaInfos
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairInterventionalPhase 3Recruitment openGermanyDNA Repair DisorderInfos
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairInterventionalPhase 3Recruitment openGermanyLynch SyndromeInfos
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairInterventionalPhase 3Recruitment openGermanyStage IIIA Colon Cancer AJCC v7Infos
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairInterventionalPhase 3Recruitment openGermanyStage IIIB Colon Cancer AJCC v7Infos
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairInterventionalPhase 3Recruitment openGermanyStage IIIC Colon Cancer AJCC v7Infos
NCT02912559Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairInterventionalPhase 3Recruitment openGermanyStage III Colon Cancer AJCC v7Infos
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 FusionInterventionalPhase 1/Phase 2Recruitment openFrancePancreatic Cancer Harboring NRG1 FusionInfos
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 FusionInterventionalPhase 1/Phase 2Recruitment openIsraelPancreatic Cancer Harboring NRG1 FusionInfos
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 FusionInterventionalPhase 1/Phase 2Recruitment openItalyPancreatic Cancer Harboring NRG1 FusionInfos
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 FusionInterventionalPhase 1/Phase 2Recruitment openNetherlandsPancreatic Cancer Harboring NRG1 FusionInfos
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 FusionInterventionalPhase 1/Phase 2Recruitment openNorwayPancreatic Cancer Harboring NRG1 FusionInfos
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 FusionInterventionalPhase 1/Phase 2Recruitment openPortugalPancreatic Cancer Harboring NRG1 FusionInfos
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 FusionInterventionalPhase 1/Phase 2Recruitment openSpainPancreatic Cancer Harboring NRG1 FusionInfos
NCT02919644Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.InterventionalPhase 2Recruitment openItalyCurative ResectionInfos
NCT02919644Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.InterventionalPhase 2Recruitment openItalyStage IV Colorectal CancerInfos
NCT02919787Nordic Pancreatic Cancer Trial (NorPACT) - 1InterventionalPhase 2/Phase 3Active but recruitment closedDenmarkPancreatic CancerInfos
NCT02919787Nordic Pancreatic Cancer Trial (NorPACT) - 1InterventionalPhase 2/Phase 3Active but recruitment closedFinlandPancreatic CancerInfos
NCT02919787Nordic Pancreatic Cancer Trial (NorPACT) - 1InterventionalPhase 2/Phase 3Active but recruitment closedNorwayPancreatic CancerInfos
NCT02919787Nordic Pancreatic Cancer Trial (NorPACT) - 1InterventionalPhase 2/Phase 3Active but recruitment closedSwedenPancreatic CancerInfos
NCT02928120Diagnostic Potential of Hypermethylated DNA in Colorectal CancerObservationalN/AUnknown statusDenmarkAberrant DNA MethylationInfos
NCT02928120Diagnostic Potential of Hypermethylated DNA in Colorectal CancerObservationalN/AUnknown statusDenmarkColorectal NeoplasmsInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedAustriaBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedBelgiumBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedCzechiaBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedDenmarkBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedFranceBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedGermanyBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedHungaryBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedIsraelBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedItalyBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedNetherlandsBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedNorwayBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedPolandBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedRussian FederationBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedSpainBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedTurkeyBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedUkraineBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928224Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerInterventionalPhase 3Active but recruitment closedUnited KingdomBRAF V600E-mutant Metastatic Colorectal CancerInfos
NCT02928627Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular CarcinomaObservationalN/AUnknown statusUnited KingdomHepatocellular CarcinomaInfos
NCT02931890Multicentric Randomised Trial for Resectable Gastric CancerInterventionalPhase 2Recruitment openNetherlandsGastric CancerInfos
NCT02934529Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabInterventionalPhase 3Recruitment openGermanyMetastatic Colorectal CancerInfos
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerInterventionalPhase 2Active but recruitment closedFranceAdvanced Gastric CancerInfos
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerInterventionalPhase 2Active but recruitment closedGermanyAdvanced Gastric CancerInfos
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerInterventionalPhase 2Active but recruitment closedIsraelAdvanced Gastric CancerInfos
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerInterventionalPhase 2Active but recruitment closedItalyAdvanced Gastric CancerInfos
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerInterventionalPhase 2Active but recruitment closedNetherlandsAdvanced Gastric CancerInfos
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerInterventionalPhase 2Active but recruitment closedSpainAdvanced Gastric CancerInfos
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerInterventionalPhase 2Active but recruitment closedSwitzerlandAdvanced Gastric CancerInfos
NCT02938481International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon CancerObservationalN/AActive but recruitment closedGermanyColon CancerInfos
NCT02938481International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon CancerObservationalN/AActive but recruitment closedLithuaniaColon CancerInfos
NCT02938481International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon CancerObservationalN/AActive but recruitment closedRussian FederationColon CancerInfos
NCT02938481International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon CancerObservationalN/AActive but recruitment closedUnited KingdomColon CancerInfos
NCT02945033Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High RiskInterventionalPhase 3Recruitment openFranceColorectal CancerInfos
NCT02948309Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic CancerInterventionalPhase 3Active but recruitment closedSwedenPancreatic CancerInfos
NCT02950324Does Prehabilitation Improve Exercise Performance and Insulin Resistance After Surgery for Oesophago-gastric Cancer?InterventionalNot ApplicableNot yet recruitingUnited KingdomCancerInfos
NCT02955940An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibInterventionalPhase 2Recruitment openSpainColorectal Cancer (CRC)Infos
NCT02955940An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibInterventionalPhase 2Recruitment openSpainPancreatic CancerInfos
NCT02956876Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive CancerInterventionalPhase 3Unknown statusFranceColoRectal CancerInfos
NCT02959541PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon CancerInterventionalNot ApplicableActive but recruitment closedSwedenChemotherapyInfos
NCT02959541PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon CancerInterventionalNot ApplicableActive but recruitment closedSwedenColon CancerInfos
NCT02967289IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant SettingInterventionalPhase 3Recruitment openFranceColon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)Infos
NCT02974556Proactive Management of Endoperitoneal Spread in Colonic CancerInterventionalPhase 3Not yet recruitingItalyColon CancerInfos
NCT02975141Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic CancerInterventionalPhase 1Unknown statusGermanyMetastatic Pancreatic CancerInfos
NCT02978612Adjuvant Chemotherapy In Elderly With Colon Cancer Stage IIIInterventionalPhase 2Active but recruitment closedNorwayColon CancerInfos
NCT02980510Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer PatientsInterventionalPhase 2Recruitment openFranceMetastatic Colorectal CancerInfos
NCT02992912Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic TumoursInterventionalPhase 2Unknown statusFrancePatients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )Infos
NCT02997553Fluorescence for Sentinel Lymph Node Identification in Cancer SurgeryInterventionalPhase 3Recruitment openFranceRectum CancerInfos
NCT03006926A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedFranceHepatocellular CarcinomaInfos
NCT03006926A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedGermanyHepatocellular CarcinomaInfos
NCT03006926A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedItalyHepatocellular CarcinomaInfos
NCT03006926A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedRussian FederationHepatocellular CarcinomaInfos
NCT03006926A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedSpainHepatocellular CarcinomaInfos
NCT03006926A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaInterventionalPhase 1Active but recruitment closedUnited KingdomHepatocellular CarcinomaInfos
NCT03009227Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon CancerInterventionalNot ApplicableActive but recruitment closedRussian FederationColonic Neoplasms MalignantInfos
NCT03026140Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of SensitivityInterventionalPhase 2Recruitment openNetherlandsColon CarcinomaInfos
NCT03037385Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedBelgiumRET-altered Colon CancerInfos
NCT03037385Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFranceRET-altered Colon CancerInfos
NCT03037385Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyRET-altered Colon CancerInfos
NCT03037385Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyRET-altered Colon CancerInfos
NCT03037385Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsRET-altered Colon CancerInfos
NCT03037385Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainRET-altered Colon CancerInfos
NCT03037385Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedUnited KingdomRET-altered Colon CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedAustriaFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedAustriaOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedAustriaPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedBelgiumFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedBelgiumOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedBelgiumPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedCzechiaFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedCzechiaOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedCzechiaPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedDenmarkPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedFinlandFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedFinlandOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedFinlandPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedFranceFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedFranceOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedFrancePeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedGermanyFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedGermanyOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedGermanyPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedGreeceFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedGreeceOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedGreecePeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedIsraelFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedIsraelOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedIsraelPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedItalyFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedItalyOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedItalyPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedNorwayFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedNorwayOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedNorwayPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedPolandPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedRussian FederationFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedRussian FederationOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedRussian FederationPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSpainPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSwedenFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSwedenOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedSwedenPeritoneal NeoplasmsInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedTurkeyFallopian Tube CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedTurkeyOvarian CancerInfos
NCT03038100A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerInterventionalPhase 3Active but recruitment closedTurkeyPeritoneal NeoplasmsInfos
NCT03042169Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric CancerInterventionalPhase 3Recruitment openFranceGastric AdenocarcinomaInfos
NCT03043313Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerInterventionalPhase 2Active but recruitment closedBelgiumMetastatic Colorectal AdenocarcinomaInfos
NCT03043313Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerInterventionalPhase 2Active but recruitment closedFranceMetastatic Colorectal AdenocarcinomaInfos
NCT03043313Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerInterventionalPhase 2Active but recruitment closedItalyMetastatic Colorectal AdenocarcinomaInfos
NCT03043313Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerInterventionalPhase 2Active but recruitment closedSpainMetastatic Colorectal AdenocarcinomaInfos
NCT03043950Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)ObservationalN/AActive but recruitment closedGermanyMetastatic Colorectal CancerInfos
NCT03044223Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa SepsisObservationalN/AUnknown statusGermanyPseudomonas Gastrointestinal Tract InfectionInfos
NCT03044587Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract CancerInterventionalPhase 2Active but recruitment closedGermanyNon-Resectable Hepatocellular CarcinomaInfos
NCT03045107Intracorporeal or Extracorporeal Anastomosis After Laparoscopic Right Colectomy.InterventionalNot ApplicableUnknown statusItalyColon CancerInfos
NCT03047837A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients.InterventionalPhase 2Unknown statusItalyTertiary Prevention in Colon CancerInfos
NCT03051152D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric AdenocarcinomaInterventionalNot ApplicableNot yet recruitingItalyGastric CancerInfos
NCT03052335The Efficiency of Colon Capsule Endoscopy in Colon Cancer ScreeningInterventionalNot ApplicableUnknown statusCzechiaColon CancerInfos
NCT03069508Clemizole HCl for Subjects With Hepatocellular CarcinomaInterventionalPhase 2Unknown statusTurkeyHepatocellular CarcinomaInfos
NCT03069664Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic CancerInterventionalNot ApplicableRecruitment openFinlandPancreatic CancerInfos
NCT03069664Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic CancerInterventionalNot ApplicableRecruitment openFinlandPancreatic Duct StrictureInfos
NCT03070613Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and SurgeryInterventionalEarly Phase 1Unknown statusUnited KingdomColorectal CancerInfos
NCT03081143Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative ChemotherapyInterventionalPhase 2/Phase 3Recruitment openAustriaAdvanced Gastric or EGJ CancerInfos
NCT03081143Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative ChemotherapyInterventionalPhase 2/Phase 3Recruitment openGermanyAdvanced Gastric or EGJ CancerInfos
NCT03083002Risk of Hepatocellular Carcinoma in Patient With Liver CirrhosisObservationalN/AUnknown statusItalyCarcinoma, HepatocellularInfos
NCT03083951Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL)InterventionalNot ApplicableActive but recruitment closedSpainColorectal CancerInfos
NCT03083951Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL)InterventionalNot ApplicableActive but recruitment closedSpainSigmoid CancerInfos
NCT03088150COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal AblationInterventionalNot ApplicableRecruitment openNetherlandsColoRectal CancerInfos
NCT03088150COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal AblationInterventionalNot ApplicableRecruitment openNetherlandsLiver Metastasis Colon CancerInfos
NCT03089268Molecular and Histological Characteristics of Serrated Lesions of the ColonObservationalN/AActive but recruitment closedSpainColorectal CancerInfos
NCT03096054A CR-UK Phase I Trial of LY3143921InterventionalPhase 1Recruitment openUnited Kingdoma. Colorectal CancerInfos
NCT03096054A CR-UK Phase I Trial of LY3143921InterventionalPhase 1Recruitment openUnited Kingdomh. Pancreatic CancerInfos
NCT03097224Prehabilitation in Frail Colon CancerInterventionalNot ApplicableUnknown statusBelgiumColon CancerInfos
NCT03097224Prehabilitation in Frail Colon CancerInterventionalNot ApplicableUnknown statusBelgiumFragilityInfos
NCT03098758Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric CancerObservationalN/AUnknown statusSpainGastric CancerInfos
NCT03098758Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric CancerObservationalN/AUnknown statusSpainPolymerase Chain ReactionInfos
NCT03113318Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal CancerInterventionalNot ApplicableRecruitment openDenmarkColorectal CancerInfos
NCT03113318Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal CancerInterventionalNot ApplicableRecruitment openDenmarkLung NeoplasmsInfos
NCT03113318Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal CancerInterventionalNot ApplicableRecruitment openDenmarkNeoplasm MetastasisInfos
NCT03117972Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 LevelsInterventionalPhase 2Recruitment openFranceMetastatic Colorectal CancerInfos
NCT03124212Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in SwitzerlandObservationalN/ARecruitment openSwitzerlandHereditary Breast and Ovarian CancerInfos
NCT03124212Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in SwitzerlandObservationalN/ARecruitment openSwitzerlandLynch SyndromeInfos
NCT03126812Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerInterventionalPhase 1/Phase 2Recruitment openNetherlandsPeritoneal CancerInfos
NCT03133273Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM)InterventionalNot ApplicableRecruitment openFranceChemotherapyInfos
NCT03133273Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM)InterventionalNot ApplicableRecruitment openFranceColorectal Cancer MetastaticInfos
NCT03133650A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble SwallowingInterventionalPhase 1Recruitment openIsraelEsophagogastric CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedAustriaVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedCzechiaVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedDenmarkVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedFranceVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedItalyVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedPolandVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedPortugalVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedRomaniaVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedRussian FederationVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedSpainVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedTurkeyVarious Advanced CancerInfos
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinInterventionalPhase 3Active but recruitment closedUnited KingdomVarious Advanced CancerInfos
NCT03146338Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)InterventionalNot ApplicableActive but recruitment closedFranceMetastatic Colorectal CancerInfos
NCT03151252Improvement of Foodallergy Diagnostic in Gastrointestinal TractInterventionalNot ApplicableRecruitment openGermanyFood AllergyInfos
NCT03153280Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal CancerInterventionalPhase 1Recruitment openIrelandColorectal NeoplasmsInfos
NCT03153280Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal CancerInterventionalPhase 1Recruitment openIrelandEsophageal NeoplasmsInfos
NCT03153280Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal CancerInterventionalPhase 1Recruitment openIrelandStomach NeoplasmInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openDenmarkColon CancerInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openFranceColon CancerInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openGermanyColon CancerInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openIsraelColon CancerInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openItalyColon CancerInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openSpainColon CancerInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openSwitzerlandColon CancerInfos
NCT03157128A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)InterventionalPhase 1/Phase 2Recruitment openUnited KingdomColon CancerInfos
NCT03158779Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic CancerInterventionalPhase 2Active but recruitment closedItalyPancreatic CancerInfos
NCT03166436RFA for Malignant Biliary ObstructionInterventionalNot ApplicableUnknown statusCzechiaPancreas CancerInfos
NCT03167268Panitumumab Skin Toxicity Prevention TrialInterventionalPhase 2Active but recruitment closedItalyColorectal Cancer MetastaticInfos
NCT03167814Prevention of Chyle-leak After Major Pancreatic SurgeryInterventionalNot ApplicableRecruitment openFinlandPancreatic CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedBelgiumColorectal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedBelgiumGastric CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedBelgiumHepatocellular CarcinomaInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedBelgiumLower Esophageal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFranceColorectal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFranceGastric CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFranceHepatocellular CarcinomaInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFranceLower Esophageal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyColorectal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyGastric CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyHepatocellular CarcinomaInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyLower Esophageal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyColorectal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyGastric CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyHepatocellular CarcinomaInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedItalyLower Esophageal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsColorectal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsGastric CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsHepatocellular CarcinomaInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedNetherlandsLower Esophageal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainColorectal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainGastric CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainHepatocellular CarcinomaInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainLower Esophageal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedUnited KingdomColorectal CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedUnited KingdomGastric CancerInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedUnited KingdomHepatocellular CarcinomaInfos
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedUnited KingdomLower Esophageal CancerInfos
NCT03174405Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.InterventionalPhase 2Active but recruitment closedGermanyMetastatic Colorectal CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openFinlandGastric CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openFranceGastric CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openHungaryGastric CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openItalyGastric CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openRussian FederationGastric CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openSpainGastric CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openUkraineGastric CancerInfos
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsInterventionalPhase 1/Phase 2Recruitment openUnited KingdomGastric CancerInfos
NCT03178812Role of the Cystic Fluid Interleukins and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS)InterventionalNot ApplicableUnknown statusIsraelPancreatic CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedBelgiumColorectal CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedBelgiumPancreatic CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFranceColorectal CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedFrancePancreatic CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyColorectal CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedGermanyPancreatic CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainColorectal CancerInfos
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsInterventionalPhase 1/Phase 2Active but recruitment closedSpainPancreatic CancerInfos
NCT03186326Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic CancerInterventionalPhase 2Active but recruitment closedFranceMetastatic Colorectal CancerInfos
NCT03189576Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of MetastasesInterventionalNot ApplicableActive but recruitment closedFinlandColorectal CancerInfos
NCT03189576Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of MetastasesInterventionalNot ApplicableActive but recruitment closedFinlandResidual DiseaseInfos
NCT03191110The COLON Study: Colorectal Cancer CohortObservationalN/ARecruitment openNetherlandsColorectal Neoplasms MalignantInfos
NCT03193190A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)InterventionalPhase 1/Phase 2Recruitment openGermanyPancreatic AdenocarcinomaInfos
NCT03193190A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)InterventionalPhase 1/Phase 2Recruitment openSpainPancreatic AdenocarcinomaInfos
NCT03200834Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)InterventionalNot ApplicableRecruitment openUkraineColon CancerInfos
NCT03202758Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRCInterventionalPhase 1/Phase 2Unknown statusFranceColorectal Cancer MetastaticInfos
NCT03205735The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic LineObservationalN/ARecruitment openFranceMetastatic or Locally-advanced Digestive CancerInfos
NCT03207867A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaInterventionalPhase 2Active but recruitment closedAustriaMSS, Microsatellite Stable Colon CancerInfos
NCT03207867A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaInterventionalPhase 2Active but recruitment closedAustriaPancreatic CancerInfos
NCT03207867A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaInterventionalPhase 2Active but recruitment closedBelgiumMSS, Microsatellite Stable Colon CancerInfos
NCT03207867A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaInterventionalPhase 2Active but recruitment closed